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Chapter 1: Introduction 
 
The Wnt/β-catenin pathway 
The Wnt pathway is typically divided into two arms, the canonical and non-canonical 
Wnt pathways. Both pathways serve to transmit an extracellular signal, a Wnt ligand, to the 
nucleus via different mechanisms. In humans, there are 19 Wnts ligands, and the first Wnt, 
Wnt-1 (int-1) was discovered as the gene activated by the insertion of mouse mammary tumor 
virus elements in virally-induced mouse mammary tumors1. The Wnts are secreted 
glycoproteins that can activate or repress canonical or non-canonical signaling, depending on 
the Wnt ligand and the receptor/co-receptor combination that is bound2; 3. The canonical, or β-
catenin dependent, Wnt pathway regulates cell fate during development and cellular 
homeostasis in adult tissues, and canonical Wnt pathway dysregulation is seen in many cancer 
types (reviewed in Anastas and Moon, 2013)4. The canonical Wnt pathway transmits 
extracellular Wnt signals to the nucleus via effects on β-catenin levels and localization5. In the 
remainder of my thesis, when I discuss the Wnt pathway, it will be in reference to the 
canonical, β-catenin dependent pathway. 
β-catenin (encoded by the CTNNB1 gene) was first identified as the Drosophila protein, 
armadillo, that played a key role in body patterning and in the assembly and function of 
adherens junctions6-8. Armadillo mutants were found to have a similar phenotype to wingless 
(Drosophila int-1 homolog9) mutants and armadillo protein accumulated in cells that expressed 
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wingless7; 8.  This led to the conclusion that the wingless and armadillo proteins cooperate in 
the cell, and specifically, that armadillo protein stability is dependent on wingless; or in 
vertebrate terms, that β-catenin protein stability is dependent on a Wnt signal. In the absence 
of an activating Wnt ligand, a complex of proteins assembles in the cell to phosphorylate β-
catenin at multiple residues in its amino-terminal domain. The phosphorylated β-catenin is then 
recognized by a ubiquitin ligation protein complex and subsequently targeted for degradation 
by the proteasome10. Amongst other proteins, APC11-14, AXIN115; 16, and AXIN217; 18 provide a 
scaffold for the assembly of a β-catenin destruction complex, while GSK3β and CKI are 
responsible for phosphorylating β-catenin19-22. The phosphorylation of β-catenin occurs at four 
residues: S33, S37, T41, and S45, and mutation of these residues prevents phosphorylation, 
rendering β-catenin resistant to degradation and thus, constitutively activated23; 24.   
When an activating Wnt ligand is present, the destruction complex is inhibited5 and the 
“free”, signaling pool of β-catenin accumulates and translocates to the nucleus, where β-
catenin binds to TCF/LEF transcription factors to modulate the expression of target genes 
(Figure 1.1)25-27. If and how the destruction complex disassembles and β-catenin becomes 
“free” is still debated28. However, the prevailing model is that upon Wnt ligand binding to the 
LRP receptor, the receptor is phosphorylated by GSK3β and CKI and destruction complex 
components, such as the AXIN proteins, are re-localized to the cell membrane where they bind 
to LRP and Dishevelled29. This re-localization of destruction complex proteins reduces the 
number of functional destruction complexes available, so newly synthesized β-catenin will not 
be bound, phosphorylated and targeted for degradation, but will instead be free to go to the 
nucleus to drive transcriptional programs30.  
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 The AXIN1/2 proteins and their functions 
There are two AXIN proteins: AXIN1 and AXIN2. In the case of AXIN2, the mouse protein 
is also known as conductin and the rat protein is referred to as Axil. Axin1 was initially identified 
as the locus responsible for a series of dominant “kinky” tail mouse phenotypes, all resulting 
from spontaneous retrotransposon insertions into an exon of Axin131. When co-injected with 
Wnt pathway components into the ventral side of Xenopus embryos, Axin1 mRNA inhibits 
ectopic axis formation, identifying the protein as a negative regulator of Wnt signaling32. The 
primary function of AXIN1 in the Wnt pathway is in the assembly of the β-catenin destruction 
complex, thus inhibiting the expression of Wnt- and β-catenin-dependent target genes. 
Aberrant activation of the Wnt pathway and dysregualtion of β-catenin protein levels and 
localization is widely presumed to be a main driver of colorectal cancer (CRC). Because AXIN1 is 
a negative regulator of β-catenin, AXIN1 has been classically thought of as a tumor suppressor 
protein. Experiments in CRC and hepatocellular carcinoma (HCC) cell lines showed that ectopic 
expression of Axin1 can cause growth suppression, reduce total β-catenin protein levels and 
inhibit a TCF-responsive luciferase reporter33. Additionally, a mouse model of loss of Axin1 in 
the liver has an increased risk of liver cancer34, further evidence of a role for AXIN1 in tumor 
inhibition. 
AXIN2 was initially identified by yeast-two-hybrid interactions with β-catenin and GSK3β 
and named for its homology to AXIN117; 18. AXIN2, like AXIN1, acts as a scaffold to help assemble 
the β-catenin destruction complex, and the two proteins how high similarity to one another in 
several domains (see Figure 1.2). Similar to AXIN1, AXIN2 negatively regulates β-catenin-
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dependent Wnt signaling. Injection of the rat Axil cDNA in Xenopus inhibits the axis duplication 
caused by activated Wnt signaling, and dorsal Axil cDNA injection results in ventralized 
embryos18. The two AXIN proteins are considered functionally equivalent, as an Axin2 cDNA 
inserted into the Axin1 mouse locus rescues the Axin1-null lethality35. However, while the 
Axin1-null mouse is lethal in embryogenesis at e9.536; 37, mice carrying homozygous null 
mutations in Axin2 are viable and fertile, with a mild skull abnormality, indicating that the two 
genes are not redundant in vivo38. This difference in phenotypes is likely due to the differential 
expression patterns of the two genes. The expression of AXIN1 is ubiquitous in various tissues32, 
while AXIN2 shows a more restricted developmental and cell-type-specific expression pattern18. 
Uniquely, AXIN2, but not AXIN1, is a robust transcriptional target of β-catenin-dependent Wnt 
signaling39-41, and AXIN2 expression is elevated in cancers with activating Wnt pathway 
mutations. Because AXIN2 is positively regulated by upstream Wnt- and β-catenin-dependent 
signals and because the AXIN proteins are the least abundant members of the destruction 
complex42, changes in AXIN2 protein levels could be a key negative feedback mechanism for the 
regulation of Wnt/β-catenin signaling in cells.  
The AXIN proteins contain multiple conserved functional domains. Starting at the N-
terminus is the Tankyrase (TNKS) binding domain which contains two discrete sequences that 
regulate AXIN protein stability43. The AXIN proteins interact with TNKS, which modifies AXINs by 
the addition of a poly(ADP-ribose) molecule(ref). This PARsylation then directs the AXIN 
proteins for ubiquitination and degradation44; 45. The RGS domain is named for the Regulators 
of G-protein Signaling protein family. This domain interacts with a specific form of the G-
alpha12 protein, but unlike other RGS-containing proteins, experiments with AXIN1 showed 
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that it does not regulate the GTP-ase activity of this G-protein46. The RGS domain of AXIN1/2 is 
most known for mediating binding to APC17. Near the center of the AXIN1 or AXIN2 protein is 
the β-catenin-binding domain17; 18, and at the C-terminus is the DIX domain, a dimerization 
domain named for two proteins which share this motif - Dishevelled and AXIN16; 17; 47-49. 
The classical view of the AXIN proteins has been that they function as tumor suppressors 
via inhibition of Wnt signaling. Other in vitro and mouse studies suggest the contrary; that 
AXIN2, in particular, which is highly expressed in cancer cells with gain-of-function Wnt 
pathway mutations, could promote tumor phenotypes such as invasion or metastasis50; 51. 
However, in a study of CRCs, AXIN2 expression had no correlations with survival or prognostic 
factors, so the clinical significance of AXIN2 expression changes in cancer is unclear52. While the 
Axin2-null mouse has no reported cancer phenotype, studies with mammary stem cells have 
shown that Axin2-null cells have a sustained response to Wnt ligands and that Axin2-null 
mammary stem cells outcompete wild-type cells to repopulate the mammary fat pad53. 
Additionally, stabilization of AXIN1 and AXIN2 protein in breast cancer cell lines inhibited Wnt 
signaling, migration, and under low serum conditions, reduced colony formation54. Moreover, 
using a wound-healing model, it was shown that Axin2-null mice display increased Wnt 
signaling and cell proliferation, and decreased cell death when compared to heterozygous 
mice55.  Taken together, these data suggest that loss of AXIN2 expression or function, rather 
than increased AXIN2 expression, would confer favorable traits to cancer cells. 
 
Both AXIN1 and AXIN2 have been implicated in non-Wnt signaling pathways. AXIN1 has 
been reported to inhibit Ras/ERK signaling, although the effect appeared to be dependent on β-
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catenin so it is not clear if AXIN plays a direct role in the modulation of ERK signaling56.  A 
second study linking AXIN1 to Ras regulation found that both AXIN1 and APC can promote Ras 
degradation via the same E3-ligase that targets β-catenin57. AXIN1 has also been show to 
interact with MEKK1 and MEKK4 and to activate JNK when overexpressed58; 59. AXIN2 has also 
been implicated in other cellular functions including repression of the MYC gene via 
competition with β-catenin for TCF factors60, regulation of the Wnt pathway in a cell-cycle 
dependent manner61 and genomic instability62.  
 
The Wnt pathway and colorectal cancer 
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the U.S. 
with a five-year survival rate of 64.7% (http://seer.cancer.gov/statfacts/html/colorect.html).  
Mutations that lead to Wnt pathway activation are found in approximately 90% of sporadic 
CRCs63, and germline, inactivating mutations in the APC gene cause the familial colon cancer 
syndrome: familial adenomatous polyposis (FAP)12. Activation of the Wnt pathway is believed 
to be one of the important first steps in the genesis of CRC64 and this key role is well-supported 
by mouse models harboring mutations in Apc.  Loss of APC is believed to activate the Wnt 
pathway by inhibiting the assembly of the β-catenin destruction complex, thus increasing the 
levels of “free” β-catenin which activate a transcriptional program that drives cell proliferation 
and survival.  In tumors, this activation of the Wnt pathway is frequently seen as shift in β-
catenin localization from the membrane to the nucleus65.  
The most common mode of Wnt pathway activation in CRC is by complete loss of the 
APC protein by a combination of nonsense and frameshift mutations, loss of one APC copy, or 
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by transcriptional silencing63. Other Wnt pathway mutations have been reported in CRC, and 16 
Wnt pathway-associated genes were identified as mutated in CRCs by the Cancer Genome Atlas 
study of 2012 (see Appendix A)63. Indeed, mutations in both AXIN1 and AXIN2 have been 
reported in association with CRC, although the functional significance of these mutations and 
their role in cancer is largely untested (to be discussed in Chapter 2).  
 
AXIN stabilization as a cancer therapeutic 
 Because the Wnt pathway is activated in a wide variety of cancers, there has been broad 
interest in therapeutic approaches that target Wnt signaling. The Wnt pathway can be targeted 
at the level of Wnt production or Wnt response, and a number of small molecules exist that can 
activate or repress Wnt signaling66; 67. As negative regulators of the Wnt signaling pathway, the 
AXIN proteins are attractive targets, especially given the increased level of AXIN2 protein in 
most cancers with activated Wnt signaling (ref.). AXIN protein stability is regulated, in part, by 
poly-ADP-ribosylation (PARsylation). Two PARsylating enzymes, TNKS1 and TNKS2, PARsylate 
AXIN1 and AXIN243. This modification primes the AXIN proteins for ubiquitination by the E3 
ubiquitin ligase, RNF146, directing them to the ubiquitin/proteasome pathway for 
degradation44; 45. The ubiquitin-specific protease, USP34, counters RNF146 by removing 
ubiquitin molecules and stabilizing the AXIN proteins68. Regulation of this PARsylation-
dependent turnover of the AXIN proteins has been targeted with small molecules that inhibit 
the TNKS1/2 enzymes43; 69-71. TNKS inhibition with several small molecules (XAV939, JW55 and 
G007-LK) has been shown to stabilize AXIN1 and AXIN2, and to inhibit Wnt signaling in CRC 
cells: XAV939 treatment of selected CRC cell lines resulted in decreased colony formation in cell 
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lines that are dependent on Wnt signaling due to inactivating mutations in APC, but not in cell 
lines lacking Wnt pathway defects43; experiments with JW55 saw similar growth inhibition only 
in CRC cell lines with APC and CTNNB1 mutations, but not in a CRC cell line with intact Wnt 
signaling, or in the HeLa cell line; and G007-LK was shown to block cell-cycle progression, 
induce differentiation and inhibit colony formation in an APC mutant CRC cell line.  
In vivo, G007-LK reduced the expression of Wnt target genes in the small intestine and 
inhibited xenograft growth of one out of three CRC cell lines tested71. JW55 was found to inhibit 
Apc-dependent tumorigenesis in a mouse model of CRC, implying that stabilization of the AXIN 
proteins could be a treatment option for cancers with APC mutations69. Presumably, the 
increased levels of the AXIN scaffold proteins can compensate for the loss of the APC scaffold 
and increase the number of functional β-catenin destruction complexes in the cell. 
Furthermore, the TNKS inhibitor JW74 was found to stabilize AXIN2 in osteosarcoma cell lines, 
resulting in differentiation and a decrease in proliferation70. Together, these data suggest that 
small molecules that stabilize the AXIN proteins could be useful therapeutics for CRC and other 
cancers with activated Wnt signaling. Whether or not AXIN stabilization has any effects on 
normal tissues and stem cells remains to be determined, although staining of normal mucosa in 
JW55 treated mice suggests that there is no effect on proliferation or the expression of 
intestinal stem cell markers69.  
 
Concluding remarks 
 The canonical Wnt pathway is an important regulator of differentiation and cell fate and 
aberrations in the Wnt pathway are seen in many cancers. Wnt signaling transmits cellular 
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responses via the effector molecule β-catenin. A β-catenin destruction complex composed of 
APC and the AXIN proteins restricts the levels of β-catenin that are free to go to the nucleus, 
thus regulating Wnt signaling. Germline mutations in APC lead to an inherited CRC syndrome, 
and somatic mutations in APC or other genes that activate Wnt signaling are seen in roughly 
90% of sporadic CRCs. Modulation of the Wnt pathway has potential for the prevention or 
treatment of cancers, and the AXIN proteins have been proposed as specific targets for 
inhibition of the Wnt pathway, although their role in cancer is still debated. In my thesis work, I 
have addressed this question by testing the functional consequences of a CRC-associated 
germline AXIN2 mutation on AXIN2 protein function, and by examining the effects of loss of 
Axin2 in a mouse model of CRC.  
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Figure 1.1- Schematic of Canonical Wnt/β-catenin signaling  
In the absence of an activating Wnt ligand (left), β-catenin is bound by the β-catenin 
destruction complex, phosphorylated, and targeted for ubiquitin-mediated degradation. When 
an activating Wnt ligand is present (right), AXIN molecules are recruited to the plasma 
membrane and β-catenin is free to translocate to the nucleus where it interacts with TCF/LEF 
factors to activate specific target genes, including AXIN2.   
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*potential GSK3β phosphorylation site 
 
Figure 1.2- Conservation of important functional domains in the AXIN proteins 
Functional domains of AXIN1/2 are boxed in with amino acid conservation measured by 
Gonnet72 PAM 250 scores: >1.5 (+), 0.5 to 1.5 (:), 0.5 to -0.5 (.). 
AXIN1      -MNIQEQGFPLDLGASFTEDAPRPPVPGEEGELVSTDPRPASYSFCSGKGVGIKGETSTA 59 
AXIN2      MSSAMLVTCLPDPSSSFREDAPRPPVPGEEGETPPCQPG-------VGKGQVTKPMPVSS 53 
             .        * .:** **************  . :*         ***   *  . :: 
 
AXIN1      TPRRSDLDLGYEPEGSASPTPPYLKWAESLHSLLDDQDGISLFRTFLKQEGCADLLDFWF 119 
AXIN2      NTRRNEDGLG-EPEGRASPDSPLTRWTKSLHSLLGDQDGAYLFRTFLEREKCVDTLDFWF 112 
           ..**.: .** **** *** .*  :*::******.****  ******::* *.* ***** 
 
AXIN1      ACTGFRKLEPCDSNEEKRLKLARAIYRKYILDNNGIVSRQTKPATKSFIKGCIMKQLIDP 179 
AXIN2      ACNGFRQMN---LKDTKTLRVAKAIYKRYIE-NNSIVSKQLKPATKTYIRDGIKKQQIDS 168 
           **.***:::    :: * *::*:***::**  **.***:* *****::*:. * ** **. 
 
AXIN1      AMFDQAQTEIQATMEENTYPSFLKSDIYLEYTRTGSESPKVCSDQSSGSGTGKGISGYLP 239 
AXIN2      IMFDQAQTEIQSVMEENAYQMFLTSDIYLEYVRSGGENTAYMSN--GGLGSLKVVCGYLP 226 
            **********:.****:*  **.*******.*:*.*..   *:  .* *: * :.**** 
 
AXIN1      TLNEDEEWKCDQDMDEDDGRDAAPPGRLPQKLLLETAAPRVSSSRRYSEGREFRYGSWR- 298 
AXIN2      TLNEEEEWTCADFKCKLS----------PTVVGLSSKTLRATASVRSTETVDSGYRSFKR 276 
           ****:***.* :   : .          *  : *.: : *.::* * :*  :  * *::  
 
AXIN1      -EPVNPYYVNAGYALAPATSANDSEQQSLSSDADTLSLTDSSVDGIPPYRIR--KQHRRE 355 
AXIN2      SDPVNPYHIGSGYVFAPATSANDSEISSDALTDDSMSMTDSSVDGIPPYRVGSKKQLQRE 336 
            :*****::.:**.:********** .* :   *::*:************:   ** :** 
 
AXIN1      MQESVQVNGRVPLPHIPRTYRVPKEVR-VEPQKFAEELIHRLEAVQRTREAEEKLEERLK 414 
AXIN2      MHRSVKANGQVSLPHFPRTHRLPKEMTPVEPATFAAELISRLEKLKLELESRHSLEERLQ 396 
           *:.**:.**:*.***:***:*:***:  *** .** *** *** ::   *:...*****: 
 
AXIN1      RVRMEEEGEDGDPSSGPPGPCHKLPPAPAWHHFPPRCVDMGCAGLRDAHEENPESILDEH 474 
AXIN2      QIREDEEREGSELTLNSR---EGAPTQHPLSLLPS-----------GSYEEDPQTILDDH 442 
           ::* :** *..: : ..    .  *.  .   :*.           .::**:*::***:* 
 
AXIN1      VQRVLRTPGRQSPGPG-----HRSPDSGHVAKMP----VALGG----AASGHGKHVPKSG 521 
AXIN2      LSRVLKTPGCQSPGVGRYSPRSRSPDHHHHHHSQYHSLLPPGGKLPPAAASPGACPLLGG 502 
           :.***:*** **** *      ****  *  :      :. **    **:. *     .* 
 
AXIN1      AKLDAAGLHHHRHVHHHVHHSTARPKEQVEAEATRRAQSSFAWGLEPHSHGARSRGYSES 581 
AXIN2      KGFVTKQTTKHVHHHYIHHHAVPKTKEEIEAEATQRVHCFCPGGSEYYCY-SKCKSHSKA 561 
             : :    :* * *:  **:..:.**::*****:*.:.  . * * :.: ::.:.:*:: 
 
AXIN1      VGAAPNASDGLAHSGKVGVACKRNAKKAESGKSASTEVPGAS----------EDAEKNQK 631 
AXIN2      PETMP--SEQFGGS-RGSTLPKRNGKGTEPGLALPAREGGAPGGAGALQLPREEGDRSQD 618 
             : *  *: :. * : ..  ***.* :*.* : .:.  **.          *:.::.*. 
 
AXIN1      IMQWIIEGEKEISRHRRTGHGSSGTRKPQPHENSRP-----LSLEHPWAGPQLRTSVQP- 685 
AXIN2      VWQWMLESER---QSKPKPHSAQSTKKAYPLESARSSPGERASRHHLWGGNSGHPRTTPR 675 
           : **::*.*:   : : . *.:..*:*. * *.:*.      * .* *.* . :. . *  
 
AXIN1      SHLFIQDPTMPPHPAPNPLTQLEEARRRLEEEEKRASRAPSKQRYVQEVMRRGRACVRPA 745 
AXIN2      AHLFTQDPAMPPLTPPNTLAQLEEACRRLAEVSK-----PPKQRCCVASQQRD----RNH 726 
           :*** ***:*** ..**.*:***** *** * .*     *.***      :*.    *   
 
AXIN1      CAPVLHVVPAVSDMELSETETRSQRKVGGGSAQPCDSIVVAYYFCGEPIPYRTLVRGRAV 805 
AXIN2      SATVQTGATPFSNPSLAPEDHKEPKKLAGVHALQASELVVTYFFCGEEIPYRRMLKAQSL 786 
           .*.*   ....*: .*:  : :. :*:.*  *  ...:**:*:**** **** :::.::: 
 
AXIN1      TLGQFKELLTKKGSYRYYFKKVSDEFDCGVVFEEVREDEAVLPVFEEKIIGKVEKVD 862 
AXIN2      TLGHFKEQLSKKGNYRYYFKKASDEFACGAVFEEIWEDETVLPMYEGRILGKVERID 843 
           ***:*** *:***.*******.**** **.****: ***:***::* :*:****::* 
Tankyrase 
binding domain 
RGS domain 
β-catenin 
binding domain 
DIX domain 
GSK3β interaction 
domain 
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Chapter 2: AXIN1 and AXIN2 sequence alterations associated with cancer 
 
Abstract  
Mutations in the APC gene, which encodes a multi-functional protein with a well-
defined role in the canonical Wnt pathway, underlie a rare, inherited form of CRC and the 
majority of sporadic CRCs. However, not all sporadic and familial CRCs can be explained by 
mutations in APC or other genes with well-established roles in CRC. The AXIN1 and AXIN2 
proteins function in the canonical Wnt pathway, and AXIN1/2 alterations have been proposed 
as key defects in some cancers. Here, we review the AXIN1 and AXIN2 sequence alterations 
reported in association with cancer, with the goal of vetting the evidence that some reported 
variants may have key functional roles in cancer development.  
 
Introduction 
Somatic mutations in genes of the canonical, or β-catenin-dependent, Wnt pathway are 
found in approximately 90% of CRCs63. These mutations contribute to CRC development by 
stabilizing the “free” signaling pool of β-catenin via disruption of the “β-catenin destruction 
complex”, which includes the APC, AXIN, and GSK3β proteins. The most common destruction 
complex defects in CRCs are loss-of-function mutations in the APC tumor suppressor gene, 
although a subset of CRCs have CTNNB1 mutations encoding a mutant β-catenin protein that is 
resistant to regulation by the destruction complex63. While APC is the most frequently mutated 
  13 
Wnt pathway tumor suppressor gene, both germline and somatic mutations in the AXIN1 or 
AXIN2 genes have been identified in a subset of CRCs and in several other cancer types. 
Following the first reports of AXIN1/2 mutations in cancer, other studies have been completed 
and AXIN1/2 sequence polymorphisms in the general population have been better defined. 
Many of the previously reported “mutations” in AXIN1/2 have now been included in dbSNP73, 
suggesting that rather than somatic alterations, these sequence changes are likely germline 
polymorphisms. The following is a comprehensive update of the reported constitutional and 
somatic AXIN1 and AXIN2 sequence variants described thus far, in order to better understand 
which of the sequence variants are most likely to confer functional consequences for cancer. 
 
Colorectal Cancer - Germline Mutations in AXIN1/2 
Inactivating mutations in the APC gene are the most frequent mechanism for activating 
the Wnt pathway in CRCs, with about 80% of CRCs harboring somatic APC mutations63.  About 
0.5-1.0% of CRCs arise in individuals with FAP, who carry an inactivating germline APC 
mutation74. Colon and rectal adenomas and CRCs arise in those individuals with FAP, in part, 
due to somatic genetic or epigenetic inactivation of the remaining wild-type APC allele, leading 
to outgrowth of cells with no functional APC alleles and dysregulated β-catenin levels. However, 
germline APC mutations only account for a subset of the CRC cases with a hereditary 
component. AXIN1 was analyzed as a candidate gene that might harbor CRC-associated 
germline mutations in a set of 124 CRC patients from the UK75. Several silent mutations were 
identified as well as seven heterozygous, missense mutations in various exons. Four of these 
mutations were found only in patients, while the other three were also found in controls, but at 
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lower frequencies. One of the patient-specific mutations has also been described in CRC cell 
lines76 and is suggested to interfere with the interaction of AXIN1 and GSK3β77. The four 
patient-specific mutations have since been added to dbSNP. 
There are only three reported germline mutations in AXIN2 that have been associated 
with CRC risk (see Table 2.1 for more detailed information). The first is a premature stop codon 
in exon 7 that was found in a family with oligodontia (the absence of multiple adult teeth) and a 
strong history of CRC78. The CRC phenotype in this family was variable, and the age at CRC 
diagnosis for carriers ranged from 27 to 64 years. A second report of a family with oligodontia 
and a CRC risk found another premature stop codon, also in exon 779. This family also had a 
variable cancer phenotype including one case of early-onset breast cancer. A third germline 
AXIN2 mutation was found in a family with an apparently milder form of familial polyposis, 
known as attenuated FAP. Of note, this family had no oligodontia or ectodermal dysplasia 
phenotype80. The AXIN2 mutation in this third family was a missense mutation in exon 5 with 
possible deleterious effects. However, the role for this AXIN2 mutation in tumorigenesis seems 
quite uncertain, as the mutant allele was lost in adenomas and polyps from the proband and his 
sister. The three reported germline AXIN2 mutations are heterozygous, suggesting that AXIN2 
mutation could perhaps predispose to cancer via a classical tumor suppressor model where the 
second allele is inactivated during tumor formation. However, loss of the wild-type AXIN2 allele 
was not seen in the missense mutation family (third family), and the state of the wild-type 
AXIN2 alleles has not been studied in cancer tissues from individuals carrying the two different 
AXIN2 nonsense mutations. It is also possible that the nonsense alleles could produce truncated 
proteins with dominant or haplo-insufficient effects.  
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A 2005 paper aimed to counter some prior reports suggesting that constitutional AXIN2 
sequence variants play an important role in CRC development. Specifically, the paper reported 
that analysis of 82 probands from families with hereditary CRC revealed 20 AXIN2 sequence 
variants in 19 individuals81. Silent and intronic mutations were ruled non-pathogenic and none 
of the identified missense mutations were enriched in patient populations when compared to 
controls. The authors thus concluded that germline AXIN2 mutations are not associated with an 
increased CRC risk. While the findings in this 2005 paper do not support a role for germline 
AXIN2 mutations in CRC risk, the collection of familial CRC cases studied was moderate and 
none of the probands had oligodontia. Another paper reporting on analysis of 31 patients with 
multiple adenomas or CRC found two notable AXIN2 germline variants in a single patient, but 
neither variant was clearly pathogenic based on Polyphen analysis: T510T and N412S82, and the 
N412S allele is now included in dbSNP.  
 
Colorectal Cancer - Somatic Mutations in AXIN1/2 
Shortly after the identification of a role for the AXIN1 protein in the β-catenin 
destruction complex, screening of AXIN1 for mutations in selected patient samples and cell 
lines from various cancers was undertaken76. Two missense alterations were seen in the CRC 
cell lines studied. The first was S215L, found in the LS513 cell line, which also exhibited loss of 
heterozygosity (LOH) of the wild-type AXIN1 allele. The second variant, L396M, was found in 
three cell lines: HCT-8, HCT-15, DLD-1, and the authors chose to follow up on this alteration 
because of the conservation of the affected amino acid and its location in the GSK3β binding 
domain. Expression of a fragment of the mouse Axin1 gene with an analogous mutation indeed 
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showed reduced binding to GSK3β, suggesting this variant allele may have functional 
consequences on the ability of the AXIN1 protein to regulate β-catenin. Because these variants 
were identified in cell lines, with no matched normal DNA, it was unclear if the AXIN1 variants 
are somatic mutations or germline polymorphisms. Both The S215L and L396M variants have 
since been listed in dbSNP, likely suggesting that these variants represent germline sequence 
variants, and not somatically acquired mutations. 
A 2002 report comparing CRCs harboring mismatch repair pathway (MMR) defects (so-
called microsatellite instability-high or MSI-H CRCs) versus CRCs with intact MMR 
(microsatellite-stable or MSS CRCs) suggested that AXIN1 mutations may be important in MSI-H 
CRCs83. Out of 33 MSI-H CRC samples studied, eight somatic, missense mutations in AXIN1 were 
found in seven tumors. No somatic mutations predicted to alter AXIN1 protein encoding 
sequences were found in the MSS samples. In the MSI-H CRCs with AXIN1 somatic mutations no 
LOH analysis was done. But, one tumor did show two different AXIN1 mutations, potentially 
representing selection for AXIN1 bi-allelic defects, perhaps akin to the situation seen for some 
tumor suppressor genes. Another study of AXIN1 mutations in 54 CRC samples reported five 
missense mutations and one nonsense mutation84. No matching normal tissue or blood samples 
were available to determine if these were somatic or germline changes. AXIN2 was not 
assessed in either study. 
A study by Liu et al. reported that 11 of 45 MSI-H CRCs tested had somatic mutations in 
AXIN285. All of the mutations were frameshifts in exon 7 mononucleotide tracts that led to 
premature stop codons in the AXIN2 open reading frame. In 60 CRCs with intact MMR, none 
contained an exon 7 AXIN2 frameshift. Only two of the eleven MMR-defective CRCs with AXIN2 
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frameshifts showed loss of the wild-type allele. This result is not unexpected because LOH is 
infrequent throughout the genome of MMR-defective CRCs86. Assuming the remaining AXIN2 
allele was not silenced by epigenetic mechanisms in the other 9 of the 11 MMR-deficient CRCs 
with a frameshift mutation in one allele, the absence of demonstrable bi-allelic AXIN2 defects 
suggests that if the AXIN2 variants were key in promoting colorectal tumorigenesis, they might 
have done so via dosage-dependent effects and/or through some potential gain-of-function of 
the truncated AXIN2 proteins encoded. The authors did not rule out nonsense-mediated decay 
for AXIN2 transcripts with premature stop codons. Of some interest, they did show that 
overexpression of a truncated AXIN2 protein, predicted to result from the frameshifts, 
promoted β-catenin accumulation in cells in culture, consistent with a possible gain-of-function 
role for the truncated AXIN2 protein.    
In an analysis of 39 sporadic MSI-H CRCs, frameshifts at c.1994 or c.1995 in the exon 
seven polyG-tract of AXIN2 were found in eight tumors87. The connection between AXIN2 exon 
7 frameshifts and MMR-deficient CRCs was further supported by a study of 310 CRCs88. 
Sequencing of exon 7 revealed heterozygous frameshift mutations in seven tumors, all of which 
were MSI-H. Four of the seven tumors also had APC mutations, perhaps raising some 
uncertainties about whether the AXIN2 frameshift mutations were functionally significant in 
CRC development or just a potential marker of the MMR-defective phenotype. Finally, a survey 
of AXIN2 sequence alterations in sporadic CRCs and some CRC cell lines identified several silent 
mutations, one 12-bp in frame deletion (del2013-2024), and potentially pathogenic frameshift 
mutation (1993del1G), which led to a premature stop at L688X89. This frameshift was seen in 
tumors with or without APC mutation, but only in MSI-H cancers, as reported previously85. The 
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12-bp deletion occurred in a MSS tumor and resulted in the in-frame loss of four amino acids, 
including two potential phosphorylation sites89.  
A study of a Kashmiri population looking for AXIN mutations in CRCs found two 
previously reported AXIN2 single nucleotide polymorphisms and a novel missense variant 
A695S90. The three patients with this sequence variant were diagnosed at ages 50, 57, and 65 
and all presented with well-differentiated tumors with LOH of the DCC region. While the 
authors reported using adjacent normal tissue in their analysis, this variant has since been 
included in dbSNP, and because it was found in 6% of the patients, it is likely a germline 
polymorphism. 
In addition to somatic sequence changes, changes in AXIN2 expression levels have been 
proposed as a potential contributing factor in CRC progression91. In a study of gene expression 
data AXIN2 expression was significantly reduced in MSI-H CRCs compared to MSS cases. Of 
note, the AXIN2 gene is directly regulated by the Wnt/β-catenin pathway, and elevated AXIN2 
expression is observed in most CRCs with APC mutations or other canonical Wnt pathway 
defects. Consistent with the gene expression data, the AXIN2 promoter was found to be 
hypermethylated in 10 out of 27 MSI-H samples, but in none of the MSS samples. Additionally 
one of the nine MSI-H CRCs with AXIN2 promoter hypermethylation had a frameshift leading to 
a premature stop codon (L688X). Ectopic expression of AXIN2 in a MSI-H CRC cell line with low 
levels of endogenous protein resulted in inhibition of cell growth, suggesting that AXIN2 may 
act as a tumor suppressor in MSI-H CRCs. A second study also found AXIN2 methylation and 
reduced expression in MSI-H CRCs92. The authors additionally reported that AXIN2 expression 
was correlated with certain clinical and pathological features of Sessile Serrated Adenomas. 
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Hepatocellular Carcinoma (HCC) and Hepatoblastoma (HB) 
Germline mutations in APC are associated with an increased risk of HB, suggesting that 
other components of the Wnt pathway may be important in HB tumorigenesis93. Sequencing of 
the AXIN1 gene in 22 HBs revealed eight exon variants, seven of which were silent94. The eighth 
variant, T58M, was also found in peripheral blood, so it may be a potentially benign 
polymorphism. A second study of sporadic HB tumors and HB cell lines found two large, out of 
frame deletions (52-bp and 1624-bp) and one somatic, missense mutation (S762N) in AXIN295. 
HCCs frequently display activated Wnt signaling, but often lack mutations in CTNNB1 or 
APC; hence, the AXIN1 gene was screened for mutations. Out of 100 primary HCCs studied, six 
AXIN1 alterations were found in five tumors, including three deletions and three premature 
stop codons33. In three of the four AXIN1-mutant tumors that could be fully analyzed, LOH of 
the wild-type AXIN1 allele was seen. Out of six HCC cell lines, two were found to contain 
deletions in both AXIN1 alleles. The authors then investigated the AXIN1 alterations in the HCC 
lines dysregulated Wnt signaling and/or cell proliferation. One of the two AXIN1-mutant HCC 
cell lines showed increased β-catenin reporter activity, and, in all six cell lines, overexpression 
of AXIN1 was growth suppressive. The authors therefore concluded that AXIN1 may act as a 
tumor suppressor in HCC.  
Further analysis of HCC and HB has revealed some additional alterations in AXIN1 and 
AXIN296. While no AXIN2 variants were seen in 27 HBs, two AXIN1 missense variants were 
found (G650S and R841Q). Both of these sequence variants have since been added to dbSNP 
with minor allele frequencies of 0.0147 and 0.0101, respectively. Even though the authors 
  20 
stated that they used matched normal samples to specifically identify somatic alterations, it is 
possible that these variants are just germline polymorphisms. In a study of 73 HCCs, seven 
somatic variants were found in AXIN1: five missense alterations, one 12-bp insertion, and a 1-
bp deletion leading to a premature stop codon. LOH of the wild-type AXIN1 allele was seen in 
four of the five AXIN1-mutant HCCs tested, further supporting a role for AXIN1 as a tumor 
suppressor in HCC. In this same collection of 73 HCCs, two AXIN2 sequence changes were 
identified, both in exon 7: a missense mutation (R659W) and a 12-bp deletion (del2013-2024). 
The 12-bp deletion has since been identified in many other cancer types, and the missense 
allele has been included in dbSNP.  
 
Gastric Carcinoma 
Because of the highly mutable mononucleotide repeats present in AXIN2, one study 
looked for exon 7 AXIN2 alterations in gastric cancers with MSI97. Nine of the 60 cancers had an 
AXIN2 frameshift mutation, and all of the cancers with an AXIN2 mutation were MSI-H. 
 
Medulloblastoma (MB) 
The incidence of MB is higher in individuals with APC mutations98. Because of the 
involvement of the Wnt pathway in MB, studies have looked for AXIN1 and AXIN2 mutations in 
MBs. Two reports identified variants in AXIN1. The first report of 86 MBs and 11 MB cell lines 
found one somatic missense alteration in exon 1 (P218S) and ten other single base pair 
changes, three that were previously identified silent polymorphisms, and four that resulted in 
amino acid changes99. The authors deemed these alterations to all be polymorphisms because 
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they were germline, rather than somatic. The study also found seven large deletions, three 
spanning exons 1-5, and four in the C-terminus. LOH studies in these MBs were inconclusive. 
A second report looked in more detail at 39 primary MBs and concluded that the 
previously reported deletions were artifacts, but that an AXIN1 SNP at nucleotide 16 of intron 4 
is significantly over-represented in MBs and could be informative100. The authors also found 
several silent variants and two missense variants in exon 1, P218S and S226C.   
Based on the work with AXIN1, a report looking for AXIN2 mutations in MB biopsies and 
cell lines found two missense mutations in exons 7 and 8 (Q696R and S738F)101. A somatic, 2-bp 
insertion in exon 5 that led to a premature stop codon (V506X) was also found in the same MB 
as the somatic, exon 7 missense mutation. Western blot analysis of this biopsy showed an 
additional, lower molecular weight band suggesting that this allele produces a truncated 
protein. Cell-based reporter assays with a C-terminal deletion suggest that these truncated 
proteins up-regulate β-catenin signaling.  
 
Ovarian Edometrioid Adenocarcinoma (OEA), Edometrial Carcinoma (EC), and Cervical 
Carcinoma (CC) 
 
A study of 30 primary OEAs and one tumor-derived cell line looked for mutations in 
AXIN1 and AXIN2102. The study primarily looked in previously identified mutation hotspots, and 
only in samples lacking APC or CTNNB1 mutations.  Sequence analysis found two potentially 
pathogenic variants in AXIN1: a nonsense mutation in exon 4 (K379X), a missense mutation in 
exon 5 (V517I), and three silent mutations including two previously published SNPs. A 
frameshift mutation was also found in exon 7 of AXIN2 (leading to L668X), and similar to 
previous reports in CRC, the AXIN2 mutation was found in a tumor with MSI103.  
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A study of 35 endometrial cancers found three variants in AXIN1, two silent and one 
causing an A360V change in exon 1104. Three sequence alterations were also found in AXIN2, 
two silent changes and one missense variant in exon 7, S658C. The authors ruled out any 
causality for these six alleles as they were all present in corresponding normal tissue. Since 
publication, the A360V variant in AXIN1 has become the reference allele.  
To assess the importance of Wnt pathway defects in cervical cancer, 30 CC samples 
were tested for mutations in CTNNB1 and AXIN1105. Six silent, germline polymorphisms and one 
missense variant were found in AXIN1. Additionally, the authors used the polymorphisms to 
look for deletions or loss of one allele, but neither was detected.  
 
Adrenocortical (AC) Carcinoma 
In a survey of 49 AC tumors and two AC carcinoma (ACC) cell lines, two SNPs and a 12-
bp deletion were found in exon 7 of AXIN2106. The same 12-bp deletion was reported in CRC 
and melanoma, and interestingly, two of the four ACC samples containing the deletion also had 
a S45 mutation in CTNNB1, as previously reported89; 107.  
 
Adenoid Cystic Carcinoma (AdCC) 
In a survey of 20 AdCC, five contained AXIN1 mutations including two tumors that 
contained the same two AXIN1 mutations, possibly representing bi-allelic targeting of AXIN1108. 
However, both mutations are in the far C-terminus of the protein, so it’s unclear if they have 
any functional consequence. No analysis was done to determine if any of the mutations were 
germline, so the incidence of the same two mutations in two patients could represent 
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polymorphisms. These AXIN1 mutations don’t appear sufficient to activate Wnt signaling as 
immunostaining for β-catenin localization showed that only one of the five AXIN1 mutant 
tumors had nuclear β-catenin, but this tumor also contained a CTNNB1 mutation.  
 
Melanoma 
A 2008 report found a germline, heterozygous mutation in AXIN2. However, this was an 
in-frame, 12-bp deletion that probably didn’t drive tumorigenesis as the tumor also had a 
somatic, hemizygous S45F CTNNB1 mutation and was MMR deficient 107. This deletion is the 
same as one previously reported in a sporadic CRC89. 
A follow-up study of 84 familial melanoma (FAM) families found six heterozygous AXIN2 
mutations109. Two of these were polymorphisms that showed similar allele frequencies in 
healthy controls. Two were intronic variants not detected in controls, but also not predicted to 
have any functional consequences. Of the remaining mutations, one was the 12-bp deletion 
previously identified in melanoma107 and the other was a missense mutation previously seen in 
HCC (R659W)96. While these mutations weren’t seen in controls, analysis of affected family 
members ruled out any association of these mutations with FAM.   
 
Discussion 
The potential tumor suppressor function of the AXIN1 and AXIN2 proteins has long been 
hypothesized, based on their role in the β-catenin destruction complex. However, the 
importance of the AXIN proteins, in vivo, for the inhibition of tumor development or 
progression is not well established, and the functional consequences of AXIN1 or AXIN2 
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mutations in cancer remain largely uninvestigated. Some reported AXIN1/2 mutations can be 
deemed non-contributory in cancer development, based on the lack of a clear link to familial 
cancer predisposition or because the variants are present at similar frequencies in controls. As 
noted in Table 2.1, many of the AXIN1 mutations reported in cancers have since been added to 
the dbSNP database or identified in the 1000 Genomes Project. Further studies to compare 
allele frequencies in control and patient populations could shed light on whether these 
polymorphisms have any cancer significance. Other reported mutations need to be more 
thoroughly tested in clinical samples, human populations, and in cell culture and animal models 
to determine if they are functionally significant. Studies that address the loss of both alleles of 
AXIN1 or AXIN2 versus mutation of one allele in patient samples or animal models could help to 
clarify if AXINs function as classic “two-hit” tumor suppressor genes, or if the mutant alleles 
have a dominant effect in cancer development. A recent study found that complete loss of 
Axin1 leads to a liver cancer predisposition in a mouse model34. Combined with AXIN1 somatic 
inactivating mutations and LOH in HCCs, these data strongly support a role for AXIN1 as a tumor 
suppressor in HCC.   
In addition to the many AXIN2 mutations reported in various cancer types, a few reports 
have linked AXIN2 SNPs to the disease risk in breast, prostate, and lung cancer110-115. Further 
efforts may support the role of AXIN2 variant alleles in cancer predisposition and perhaps might 
uncover some value for the variants in informing approaches for the prevention or early 
diagnosis of cancer. The vast majority of the AXIN2 mutations in cancer have been found in 
exon 7 and many are frameshifts. Because the frameshift mutations are present in highly 
mutable mononucleotide tracts and because the mutations arise in MMR-defective CRCs, it is 
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difficult to determine whether these frameshifts, which lead to premature stop codons, play a 
role in cancer development or progression, or whether they are passenger mutations. The 
association with a major tooth phenotype and a very strong predisposition to colon and 
perhaps other cancers in some individuals carrying heterozygous, germline, truncating AXIN2 
mutations strongly suggests that these mutant alleles may be have major contributing roles in 
development and in cancer predisposition. Because the tooth phenotype is constitutional, it 
could inform on the function of these germline, truncating mutations. However, the role of the 
Wnt pathway in tooth development is complex and the tooth defect in these two families 
affects the development of a subset of secondary teeth that cannot be readily modeled in the 
mouse. Nonetheless, it is interesting to note that some FAP patients (carrying heterozygous 
APC germline mutations) will develop extra teeth and benign odontomas116. If we assume that 
the APC mutations lead to activation of Wnt signaling, then the reduction in teeth in AXIN2 
mutation carriers suggests that the AXIN2 mutant alleles might not be simple loss of function 
alleles, or that perhaps AXIN2 plays an important role outside the β-catenin destruction 
complex. Further studies of the function of the wild-type and mutant AXIN2 proteins may yield 
important clues into AXIN2 function in development and cancer.  
If the AXIN proteins are indeed important suppressors of cancer development or 
progression, then small molecules that stabilize these proteins could be a valuable treatment 
strategy. While some findings suggest that increased levels of AXIN proteins inhibit colon cancer 
cells that are dependent on β-catenin signaling, a recent mouse xenograft study suggests the 
opposite: that high levels of AXIN2 actually promote cancer cell invasion and perhaps 
metastasis 50. Without clear evidence of the pathogenicity of the mutations identified to date or 
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strong evidence from animal models, the importance of AXIN1 and AXIN2 as tumor suppressor 
genes or oncogenes in cancer remains an unresolved issue of keen interest. 
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Table 2.1- Summary of AXIN1 sequence alterations reported in cancer 
 Sequence alteration identified* Cancer type Reference Notes 
In
se
rt
io
n
s/
D
e
le
ti
o
n
s 
Deletion of exons 1-2   HCC cell line: SNU475 33 Homozygous, no transcript detected  
Deletion of exon 4  HCC cell line: Alexander 33 Homozygous 
c.178_1597del  MB 99  
c.266_1585del  MB 99 Germline 
c.355_1712del  MB 99  
c.1938_2704del  
 
MB 99 Deletion ends after stop codon 
c.2168_3098del  MB 99  
c.2426_3101del  MB 99  
c.2325_3106del  codons 346-350 MB 99  
5-bp deletion  codon 386 HCC 33   
13-bp deletion  codons 444-448  HCC 33   
25-bp deletion†  codons 485-493 HCC 33  
c.1076 del 1 bp   M418X HCC 96  
c.1714 ins 12 bp   Insert: QVHH HCC 96  
M
is
se
n
se
 
 T58M HB 94 Germline 
 L101P† CRC 83 MSI CRC, heterozygous 
 R103M  CRC 83 MSI CRC, heterozygous 
 L106R HCC 96   
 T122A CRC 83 MSI CRC, heterozygous 
 K203M‡ CRC 84   
 S215L‡ CRC cell line: LS513 76   
 P218S MB 99, 100 Somatic (99) 
 S226C MB 100   
 P263T‡ CRC 75 Heterozygous 
 N307K CRC 84  
 P345L HCC 96   
 R349H‡ CRC 75 Heterozygous 
 R353H† CRC 83 MSI CRC, heterozygous 
 A360V  EM 104 Now the reference allele 
 R382C‡ ESCC 117 Germline, seen in 2/81 patients 
 H394N CRC 84   
 R395C CRC 83 MSI CRC, heterozygous 
 L396M‡ 
CRC, CRC cell lines:  
HCT-8, HCT-15, DLD-1 75, 76 Heterozygous (75) 
 E411D CRC 83 MSI CRC, heterozygous 
 M418I CRC 83 MSI CRC, heterozygous 
 G425S‡ HCC 96   
 G433E AdCC 108  
 D495E‡ CRC 75 Heterozygous 
 V517I‡ OEA 102  
 G583S CRC 83 MSI CRC, heterozygous 
 G650S‡ HB, HCC, CRC 96, 75   
 V517I‡ OEA 102  
 P661L AdCC 108  
 A740T CC 105  
 F824K AdCC 108  
 S828G AdCC 108  
 R841Q‡ HB, CRC 96, 75 Heterozygous (75) 
 E842K AdCC 108  
 P848L CRC 84   
 E852G CRC 84   
N
o
n
-
se
n
se
  W247X HCC 33  
 Y305X CRC 84   
 E406X† HCC 33  Seen in 2/100 cases 
 K397X OEA 102  
* Nucleotide and amino acid numbering modified to match modern sequences: NM_003502.3, NP_003493.1. 
† These two mutations were found in same individual, references 33 and 83 respectively. 
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‡ These variants are now listed in dbSNP (http://www.ncbi.nlm.nih.gov/SNP). 
Table 2.2- Summary of AXIN2 sequence alterations reported in cancer 
 Sequence alteration identified* Cancer type Reference Notes 
In
se
rt
io
n
s/
D
e
le
ti
o
n
s 
52bp del delE745-S762 HB cell line D272 95  
del1624 delS217-E823 HB cell line HUH6 95  
c.2010del12bp delT672-R675 CRC 89 MSS CRC 
c.2013del12bp delR671-P674 
ACA, ACC, ACC cell line H295R, 
Melanoma cell line PR-Mel 
107, 106 
 
c.1209insAT V506X MB 101  
c.1925delA L688X CRC 88 MSI 
c.1926insA E706X† CRC  85 MSI 
c.1993delG L688X CRC 89 MSI 
c.1994delG L688X CRC, GC, OEA 85, 87, 88, 97, 102 MSI CRC, GC, OEA 
c.1995insG E706X† CRC 85, 87, 88 MSI 
c.2007delC L688X CRC 91 MSS 
c.2011delC L688X CRC 85 MSI 
c.2023delC L688X CRC 85, 88 MSI 
M
is
se
n
se
 
 N412S‡ CRC 81, 82 Also seen in controls 
 R463C CRC 80 Germline, LOH wt allele 
 A603P†,‡ CRC 81 
Germline, also seen in 
controls 
 S658C EM 104  
 R659W‡ HCC, Melanoma 96, 109  
 A695S‡ CRC 90  
 Q696R MB 101  
 S738F†,‡ CRC, MB 81, 101 Also seen in controls (81) 
 S762N‡ CRC, HB cell line D165 95, 81 Also seen in controls 
N
o
n
-
se
n
se
  R656X CRC syndrome with oligodontia 78 Germline 
 W663X CRC syndrome with oligodontia 79 Germline 
ACA/C-Adrenalcorical Adenoma/Carcinoma, AdCC-Adnoid Cystic Carcinoma, CC-Cervical Carcinoma, EM-Edometiral Carcinoma MB- 
Medulloblastoma, OEA- Ovarian Endometrioid Adenocarcinoma 
 
* Nucleotide and amino acid numbering modified to match modern sequences: NM_004655.3, NP_004646.3. 
† These two mutations were found in same individual, reference 81 and 85 respectively. 
‡ These variants are now listed in dbSNP (http://www.ncbi.nlm.nih.gov/SNP). 
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Figure 2.1- Location and amino acid conservation of AXIN1 sequence alterations reported in 
association with GI cancers 
(A) Diagram of the location of germline and somatic AXIN1 variants implicated in GI cancers. 
The locations of important functional domains in the AXIN1 protein are indicated. Missense and 
nonsense mutations are shown above the diagram, insertions and deletions are shown below. 
(B) Amino acid conservation of the reported missense variants. Conservation designated by 
Gonnet [15] PAM 250 scores: >1.5 (+), 0.5 to 1.5 (:), 0.5 to -0.5 (.), <0.5 (-). 
  30 
 
 
Figure 2.2- Location and amino acid conservation of AXIN2 sequence alterations reported in 
association with GI cancers 
(A) Diagram of the location of germline and somatic AXIN2 variants implicated in GI cancers. 
The locations of important functional domains in the AXIN2 protein are indicated. Missense and 
nonsense variants and deletions are shown above the diagram, frameshifts are shown below. 
Note the density of frameshifts in the exon 7 mononucleotide repeat regions. (B) Amino acid 
conservation of the missense variants. Conservation designated by Gonnet [15] PAM 250 
scores: >1.5 (+), 0.5 to 1.5 (:), 0.5 to -0.5 (.), <0.5 (-).  
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Chapter 3: An AXIN2 mutation associated with an autosomal dominant ectodermal dysplasia 
and neoplastic syndrome1 
 
 
Abstract 
We describe a family with a novel, inherited AXIN2 mutation (c.1989G>A) segregating in 
an autosomal dominant pattern with oligodontia and variable other findings including a mild 
ectodermal dyplasia phenotype with sparse hair and eyebrows, colon polyposis, and early onset 
colorectal and breast cancers. This novel mutation introduces a stop codon at amino acid 663, 
predicted to encode a truncated protein that is missing the last three exons, including the DIX 
(Disheveled and AXIN interacting) domain. This nonsense mutation is predicted to alter the 
inhibitory action of AXIN2 on WNT signaling. Previous authors have described an unrelated 
family with autosomal dominant oligodontia and a variable colorectal phenotype segregating 
with a nonsense mutation of AXIN2, as well as a frameshift AXIN2 mutation in an unrelated 
individual with oligodontia. Our report provides additional evidence supporting an autosomal 
dominant AXIN2-related ectodermal dysplasia and neoplastic syndrome. 
                                                          
1  Originally published as AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic 
syndrome in American Journal of Medical Genetics Part A. (2011 Apr;155A(4), 898-902) with authors 
listed as Marvin ML, Mazzoni SM, Herron CM, Edwards S, Gruber SB, and Petty EM. 
My contribution to this paper included writing the “Truncation Analysis” section, generating Figure 3.2, 
and assisting with the “Discussion” section and proof-reading of the manuscript. I cloned the AXIN2 and 
trAXIN2 cDNA expression constructs and expressed them in 293T cells to see if the truncated protein 
was stable. CM Herron performed the PCR to amplify the patient DNA.   
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Introduction 
Several inherited CRC syndromes have been described that result from germline 
mutations in tumor suppressor or mismatch repair genes. These conditions include FAP 
resulting from germline APC mutations, MYH associated polyposis resulting from biallelic 
germline MYH mutations, and Lynch syndrome, also known as hereditary nonpolyposis 
colorectal cancer syndrome, resulting from mutations in one of four mismatch repair genes, 
MSH2, MLH1, MSH6, or PMS2118; 119 . These syndromes often include extracolonic 
manifestations.  However, not all familial colon cancer cases can be attributed to these or other 
known, CRC-associated genes, suggesting that other uncharacterized cancer syndromes and 
genes remain to be described.  
Because mutations in several genes of the canonical WNT pathway (i.e. APC and 
CTNNB1 which encodes -catenin) have been implicated in colorectal tumorigenesis, other 
genes in this pathway may play a role in these uncharacterized families, including AXIN2. 
Mutations in genes of the WNT signaling pathway that prevent the degradation of -catenin 
lead to tumorigenesis by inappropriately activating WNT signaling. Within the WNT pathway, 
AXIN2 acts as a negative regulator by contributing to the assembly of the -catenin degradation 
complex120.  Somatic AXIN2 mutations have been described in a variety of human cancers, 
including colorectal cancers76; 111.85; 121  AXIN2 has also been independently implicated in tooth 
agenesis and oral clefts122-124.  
Of particular interest is the description of a large, four-generation Finnish kindred in 
which both oligodontia and a variable colorectal phenotype segregated with a nonsense 
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mutation in AXIN278.  In this family, the oligodontia phenotype (defined as congenital absence 
of six or more permanent teeth, third molars excluded) was entirely penetrant in mutation 
carriers. No other ectodermal findings such as those involving the nails, hair, or skin were 
described. The colorectal phenotype in this family was variable. Six of the seven family 
members with oligodontia had colorectal neoplasms, ranging from polyposis to colorectal 
malignancy with no polyps. Lammi et al. also screened oligodontia patients for AXIN2 mutations 
and identified a de novo germline mutation in a 13-year-old boy with oligodontia. Of note, the 
germline mutation in this patient was a 1-bp insertion in exon 7 that was identical to a 
frameshift mutation described in a colorectal cancer tissue85.  
We describe an unrelated family with an inherited AXIN2 mutation segregating in an 
autosomal dominant pattern with oligodontia and variable other findings including colonic 
polyposis, gastric polyps, a mild ectodermal dyplasia phenotype with sparse hair and eyebrows, 
and early onset colorectal and breast cancers. This report provides additional clinical 
description of and support for an autosomal dominant AXIN2-related ectodermal dysplasia and 
neoplastic syndrome. 
 
Case Report 
A 35-year-old woman presented to Medical Genetics for evaluation of a possible 
ectodermal dysplasia syndrome due to a personal history of oligodontia, including the 
congenital absence of greater than 10 secondary teeth, and a family history of oligodontia 
(Figures 3.1a and 3.1b). She reported normal body hair, normal nails, and normal sweating.  Her 
past medical history was noted for intermittent non-bloody diarrhea, gastric reflux, peptic ulcer 
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disease, iron deficiency anemia, polycystic ovary disease, decreased fertility, fibromyalgia, 
insulin resistance, fundic gland polyps, Sjogren’s disease, anxiety, and depression.  
Previous evaluations included a normal colonoscopy and upper endoscopy exams 
revealing multiple fundic gland polyps at ages 33 and 35, normal capsule endoscopy at age 34, 
and normal rheumatology and celiac sprue evaluations. Physical exam was notable for 
hypognathia, malar hypoplasia, broad nasal bridge, very sparse eyebrows, fine scalp hair, and 
slightly upslanting palpebral fissures. Oropharyngeal exam was noted for a high arched palate, 
several missing teeth with increased spacing and conical shaping of several teeth. She was 
otherwise noted to have normal body hair distribution, normal nails, and normal skin. 
Her family history was notable for oligodontia, absent eyebrows, sparse hair, colon 
polyps, early onset colon cancer, and early onset breast cancer (Figure 3.1b and Table 3.1). The 
proband’s mother (II, 2) had oligodontia with absence of most of her secondary teeth. She 
began colonoscopic screening at age 60 and was found to have greater than 100 adenomatous 
polyps requiring a sigmoid colectomy at age 60 and a right hemicolectomy at age 62. She was 
evaluated in our clinic and was also noted to have soft skin with particularly scant body hair, 
minimal axillary hair, short eyelashes, and very sparse eyebrows, especially laterally.  
The proband had two maternal aunts, including one (II, 1) with oligodontia, breast 
cancer diagnosed at age 44, metachronous colon cancers diagnosed at ages 50 and 59, and 5 
adenomatous polyps of the transverse and ascending colon at age 69. The other maternal aunt 
(II, 3) had a reported history of colon polyps, oligodontia, absent eyebrows, and sparse hair. 
Confirmation of her history was not available. The index patient’s sister (III, 2) had no dental or 
other ectodermal findings and had not undergone endoscopic screening. One cousin (III, 1) also 
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had no dental or ectodermal findings and had normal colon screening at age 41. The proband’s 
maternal grandmother (I, 2) died at age 97 with a reported history of oligodontia, absent 
eyebrows, and sparse hair, and no known history of colon polyps or cancers.  
 
Methods and Results 
Genetic Testing 
After genetic counseling and informed consent, the proband was enrolled in the 
University of Michigan Cancer Genetics Registry and a blood sample was obtained. Bidirectional 
direct sequencing of exon 7 of AXIN2 and flanking intronic regions revealed the 1989G>A gene 
alteration (W663X) (Figure 3. 2). This is a novel mutation that introduces a stop codon at amino 
acid 663.    
Following the identification of the AXIN2 mutation in the proband, her sister (III, 2), 
mother (II, 2), one maternal aunt (II, 1), and one maternal cousin (III,1) also enrolled in the 
University of Michigan Cancer Genetics Registry and underwent genetic testing for the 
c.1989G>A alteration. The proband’s mother (II, 2) and maternal aunt (II, 1) tested positive and 
her sister (III, 2) and cousin (III,1) tested negative (Table 3.1 and Figure 3.1b). The proband’s 
mother (II, 2) also underwent clinical genetic testing of the APC and MYH genes with normal 
results. APC testing included sequence analysis of exons 1-14 and the 5' end of exon 15 and 
protein truncation testing for mutations in exon 15. Gene dosage analysis (MLPA) was also 
performed to test for the presence of large deletions, duplications, and other genomic 
rearrangements. MYH testing included a PCR-based analysis (restriction enzyme digest) for the 
presence of the Y165C and G382D mutations. 
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Truncation Analysis 
The AXIN2 DNA sequence was cloned from DLD1 cDNA, PCR amplified using primers 
specific to the AXIN2 sequence, and inserted into the pCR2.1-TOPO vector (Invitrogen). The 
1989G>A mutation was introduced by site-directed mutagenesis using the QuickChangeII site-
directed mutagenesis kit (Stratagene). In vitro transcription and translation (TNT, Promega) was 
performed following manufacturer’s instructions. Biotinylated proteins were visualized 
following se paration by SDS-PAGE with streptavidin-conjugated HRP.  In vitro transcription and 
translation of the mutated construct produced an approximately 80kDa protein representing a 
truncated AXIN2 product, missing the last three exons. Further, 293T cells were transfected 
with AXIN2 or 1989G>A AXIN2 expression constructs and protein expression analyzed by 
Western blot using an AXIN2 antibody (Cell Signaling, 76G6). 
 
Discussion 
Our findings provide further evidence of an autosomal dominant multisystem 
ectodermal and neoplastic phenotype associated with a germline AXIN2 mutation. The novel 
mutation found in our family introduces a stop codon at amino acid 663.  The truncated protein 
predicted to be encoded by this mutation is missing the last three exons, including the DIX 
domain. The DIX domain is required for AXIN2 dimerization, and dimerization is believed to be 
essential for AXIN2 to act as a scaffold for the assembly of protein complexes, in particular, the 
-catenin destruction complex49. Formation of this complex is important for the inhibition and 
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negative feedback of WNT signaling, therefore, we predict that loss of the DIX domain will have 
functional consequences for the inhibitory action of AXIN2 on WNT signaling. 
Similar to the findings of Lammi et al., the oligodontia phenotype in our family is highly 
penetrant. In addition, members of our family had a mild ectodermal dysplasia phenotype 
characterized by absent or sparse eyebrows and body hair. Furthermore, three of the four 
AXIN2 mutation carriers in our family had colorectal neoplasia, including one with a modest 
number of adenomas who had two primary colon cancers in her 50’s (II,1); one with polyposis 
reminiscent of FAP (II,2); and one with an unspecified number of colon polyps  (II,3). The 
youngest mutation carrier in our family, the proband (III,3), had normal colonoscopic findings in 
her mid 30’s, but was noted to have multiple fundic gland polyps. Given that upper 
gastrointestinal screening has not been performed in other mutation carriers and that the 
proband's fundic gland polyps could be related to proton-pump inhibitor use, further 
exploration is needed to determine if fundic gland polyps are related to AXIN2 mutations125. 
The diagnosis of early onset breast cancer in one member of this family (II, 1) is 
intriguing given that others have hypothesized that genetic variation influencing the expression 
of APC and AXIN2 contributes to breast cancer risk113; 114. Supporting evidence includes the 
finding that AXIN2 maps to a chromosomal region at band 17q24 that has demonstrated allelic 
imbalance in breast cancer samples, and an increased rate of breast cancer in mouse models 
with up-regulated WNT signaling,126. Additionally, AXIN2 is involved in epithelial to 
mesenchymal transitions in mammary epithelial cells, which is thought to be a critical in the 
development of invasive and metastatic breast cancer51. It is unclear if the observed 
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development of early onset breast cancer in one member of this kindred is related to the 
germline AXIN2 mutation identified. Further studies are needed to substantiate a causal role.  
AXIN2 mutations have also been associated with the development of oral clefts, such as 
cleft lip and cleft palate. A recent analysis of 75 families found that there was a significantly 
higher incidence of cancer in families with cleft lip and palate compared to controls.  In fact, the 
rates of breast and colon cancer in these families were significantly higher127. Additional studies 
to examine the correlation of AXIN2 mutations with cleft lip/cleft palate associated with an 
increased risk of breast or colon cancer are needed to determine if a unique AXIN2-related 
syndrome of oral clefs associated with an increased risk for cancer exists.  
This report describes a second family with an AXIN2 mutation co-segregating in an 
autosomal dominant pattern with oligodontia and early onset cancers. In addition, this study 
extends the phenotypic spectrum associated with germline heterozygous AXIN2 mutations to 
include other ectodermal dyplasia features and raises the possibility of an association with 
increased breast cancer risk. Further studies are needed to determine the role of AXIN2 
mutations in inherited cancer predisposition and better characterize the phenotype associated 
with this newly recognized autosomal dominant AXIN2-associated ectodermal dysplasia 
neoplasia syndrome. Similar to other inherited cancer predisposition syndromes, a careful 
family and personal medical history is critical to developing a complete differential. The co-
occurrence of colorectal neoplasia, including polyposis and colorectal cancer, with oligodontia, 
other ectodermal dysplasia findings such as sparse hair and eyebrows, or oral clefts should 
prompt an evaluation for AXIN2 mutations.   
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Figure 3.1- Oligodontia phenotype and pedigree 
(A) Panoramic radiograph demonstrating the proband’s congenital absence of teeth 2, 7, 10, 15, 
18, 23, 24, 25, 26, 27, and 31.  (B) Autosomal dominant inheritance of oligodontia and variable 
colorectal phenotype associated with c.1989G>A.    
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Figure 3.2- c.1989G>A mutation produces a truncated protein in vitro 
(A) Sequencing of the proband’s DNA (III, 3) revealed a heterozygous mutation, c.1989G>A, 
which encodes a premature stop codon. (B) 293T cells were transfected with wild-type AXIN2 
or AXIN2 c.1989G>A cDNA constructs. Western blot of cell lysates revealed that AXIN2 
c.1989G>A produces an approximately 80kDa protein representing a truncated AXIN2 product. 
(C) Schematic of the AXIN2 protein and important binding domains shows the site of the 
identified mutation. 
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Chapter 4: A truncated AXIN2 protein- functional consequences of deletion of the DIX domain 
 
Abstract 
Two heterozygous, germline mutations in the AXIN2 gene have been identified in 
families with oligodontia and a CRC predisposition. To determine how these nonsense alleles 
might contribute to a cancer predisposition, I used the 1989G>A mutation as a model for the 
germline and somatic mutations seen in a subset of many cancers. Analysis of lymphocytes 
from an individual carrying the 1989G>A mutation suggested that the mutant transcripts 
escape nonsense-mediated decay and could then encode a truncated protein. Cell culture 
experiments using a cDNA encoding the truncated protein (trAXIN2) demonstrated that the 
truncated protein is more abundant, possibly due to increased protein stability. Unlike the wild-
type AXIN2 protein, the regulation by GSK3β that inhibits AXIN2 turnover does not seem to be a 
main source for the stabilization of the trAXIN2 protein. In zebrafish embryo injections, the 
trAXIN2 mRNA produced a developmental phenotype, suggesting that this protein is not a 
simple loss of function protein. Additionally, while the trAXIN2 protein may be hypomorphic in 
Wnt-target gene inhibition assays, it retains binding with destruction complex components and 
inhibits colony formation in a Wnt-dependent CRC cell line. These data support the conclusion 
that the germline mutations in AXIN2 could encode a truncated protein with reduced function 
that might be present in cells at a higher concentration than the wild-type protein. 
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Introduction 
In 2011 we reported a germline AXIN2 mutation associated with oligodontia and a 
colorectal cancer predisposition79. This mutation introduces a premature stop codon and 
because of the location of the mutation, this allele would be predicted to undergo nonsense-
mediated decay (NMD). NMD would support a classical tumor suppressor model where one 
allele is non-functional and the second is lost during tumor development. In addition to two 
other reports of germline AXIN2 alleles associated with CRC predisposition, somatic AXIN2 
mutations have been identified in a subset of several cancer types (reviewed in Chapter 2). The 
majority of these somatic mutations are in exon 7, near the 1989G>A mutation, and lead to 
premature stop codons. It is possible that these mutations are simple passenger mutations, but 
they could also escape NMD and have functional significance as has been seen with truncating 
mutations in APC128. We have been unable to directly assess AXIN2 protein expression in 
patient samples to determine if these truncating mutations create stable proteins, but since the 
Axin2lacZ/+ mouse lacks a haplo-insufficient phenotype38, the functional consequence of these 
truncating mutations merited further exploration. The 1989G>A germline allele was used as a 
model truncating mutation to ask how the function of the truncated protein it encodes, 
trAXIN2, differs from the wild-type protein, and whether these truncating mutations impact 
cancer development.  
 
Materials and Methods 
Expression constructs and cell culture 
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The AXIN2 sequence was cloned using cDNA isolated from the DLD-1 cell line. The 
trAXIN2 sequence was made from AXIN2 by site-directed mutagenesis and the sequences were 
cloned in to the following expression constructs: ppGS-CMV-Cite-Neo for retroviral expression; 
pCMV-3Tag for FLAG-tagged expression; and ppCS2+MT for myc-tagged expression. The AXIN1 
cDNA was cloned into pCDNA3.1 with a FLAG- and Myc-tag, and the β-catenin S33Y expression 
construct has been previously published129. 
All cells were cultured under sterile conditions at 37°C, 5% CO2. The 293T, DLD-1 (ATCC-
CCL-221), RKO (ATCC CCL-2577) and SW480 (ATCC CCL-228) cell lines were cultured in DMEM 
(GIBCO) with the addition of 10% FBS and 1% penicillin/streptomycin. IEC-6 cells (ATTC CRL-
1592) were grown in DMEM (Gibco) with the addition of 10% FBS (Fisher), 1% 
penicillin/streptomycin (Gibco), and 0.1 Unit/ml recombinant human insulin (Gibco).  
For transfection-based studies, cells were transfected in 6-well plates at 60-80% 
confluence using 2μg of total DNA per well with the TransIT-LT1 transfection reagent (Mirus). 
 
Mutant allele identification 
After obtaining informed consent, peripheral blood lymphocytes (PBLs) were isolated 
from whole blood using Ficoll-Hyaque separation. The buffy coat layer was removed and plated 
for adherence depletion of monocytes. PBLs were cultured in RPMI-1640 (Gibco) supplemented 
with 10% FBS (Fisher), 1% penicillin/streptomycin (Gibco), 1% HEPES (Gibco), 0.5% β-
mercaptoethanol (Gibco), and L-Glutamine (Gibco). PBLs were cultured for 48 hours and then 
treated with 5μM BIO (Cayman Chemical #13123) or DMSO for 18 hours.  
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Total RNA was isolated using Trizol and cDNA was generated with the High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). Genomic DNA was isolated from PBLs by 
boiling the cells in 50mM NaOH followed by neutralization with 1M Tris, pH 8.0. 
 PCR to specifically amplify gDNA or cDNA was done using Taq polymerase (Promega). 
Bulk PCR products were gel extracted and sequenced. PCR products from gDNA and cDNA were 
TOPO cloned using the pCR2.1 TOPO cloning vector (Invitrogen). Single TOPO clones were then 
isolated and sequenced to confirm the 1989GA genotype and the presence of the AXIN2 3’UTR. 
 
Table 4.1- AXIN2 PCR primers 
Primer Primer location Primer sequence 
AXIN2 gDNA forward AXIN2 intron 5 CCGACTTGCTGAATTGTCTG 
AXIN2 gDNA reverse AXIN2 intron 6 TGGATGAGTAAGCTGCTGCTT 
AXIN2 cDNA forward AXIN2 exon 6 GGGAGGAAGGAGACAGGTCGC 
AXIN2 cDNA reverse AXIN2 3’ UTR CAAAGCCAGACCCCAGGG 
 
 
Quantitative PCR (qPCR) 
For Wnt target gene analysis, IEC-6 cells were transduced with retrovirus and then 
grown under G418 selection to create stable lines. To test inhibition of β-catenin target genes, 
100,000 stable IEC-6 cells were plated in a 6cm dish. 24 hours after plating, the cells were 
treated with 200ng/ml recombinant Wnt3a (ProSci) to induce target gene expression, or with 
PBS as a control. After 16 hours of induction, RNA was collected by Trizol extraction, cDNA 
synthesized, and target genes analyzed by qPCR using the primers shown below. Target gene 
induction was measured six independent times. 
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For quantification of AXIN2 or trAXIN2 transcripts, 293T cells were transfected in 6-well 
dishes with 2μg of FLAG-tagged expression constructs. 24 hours after transfection, RNA was 
isolated for analysis by qPCR. Ectopic transcripts were quantified by detection of the FLAG 
sequence. 
 
Table 4.2- qPCR primers for Wnt target gene and AXIN2/trAXIN2 transcript quantification 
Gene Primer sequence 
U6 F- GTGCTCGCTTCGGCAGCACATAT 
R- AAAAATATGGAACGCTTCACGAA 
Axin2 (rat) F- CTCTAACGCTAGGCGGAATG 
R- CCAGAAGTCCAGGGTATCCA 
Lgr5 F- GCTGCCAAATTGTTGGTTTT 
R- CAGGCTAGAAAGGGGAGCTT 
Irs1 F- CCAGAAGCAACCAGAGGA 
R- CCATGAGTTAAAAAGGAGGAT 
Nkd1 F- AGGACGACTTCCCCCTAGAA 
R- TGCAGCAAGCTGGTAATGTC 
-actin F- GCCTTCCTTCTTGGGTATGG 
R- GCCTGGGTACATGGTGGT 
FLAG F- AAGGACGATGATGACAAGGACTACA 
R- TCCGGGAGGCAAGTCACCAA 
 
Protein interaction studies 
Cells were transfected with plasmids using TransIT-LT1 (Mirus) or Fugene-HD (Promega). 
Total protein was extracted using RIPA buffer followed by immunoprecipitation (IP) with the 
indicated antibody and protein A/G agarose with 200μg of total protein. Proteins were eluted 
from agarose by boiling in Laemmli buffer and analyzed by SDS-PAGE and Western blot. β-
catenin IPs were performed following a five-hour treatment with 10μM of the proteasome 
inhibitor, MG132 (Cayman Chemical).  
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The following antibodies were used for Western blotting: α-AXIN2 (Cell Signaling, 76G6), 
α-FLAG (Sigma, M2), α-myc (Sigma, C3956), total β-catenin (BD-Transduction Laboratories), 
phospho-33, 37, 41 β-catenin (Cell Signaling, 9561) and β-actin (Sigma, AC-15); and for IP: α-
FLAG (Sigma, F7425) and α-myc (as above).  
  For protein stabilization studies, 293T cells were plated in a 6-well dish and transfected 
at 70-90% confluence with 2μg of FLAG-tagged proteins. Six hours after transfection, each well 
was split to four wells of a six-well plate. 24 hours post-transfection, the cells were treated with 
DMSO, 100nM OA (Cell Signaling, #5934), or 1M BIO. Cells were collected for Western blotting 
after 6 hours of inhibitor treatment. XAV939 (Cayman Chemical) treatment was performed 
using the indicated concentrations and cells were collected for Western blotting after 24 hours 
of inhibitor treatment. Proteasome inhibition was tested in DLD-1 cells that stably express a 
FLAG-tagged AXIN2 or trAXIN2 protein. Cells were treated with 10μM MG132 for five hours and 
then total protein lysates were analyzed by Western blot. 
 
Colony formation assays 
Cells were transfected with vector, AXIN2, or trAXIN2 pCMV3Tag expression constructs. 
24 hours post-transfection, cell were counted, plated in triplicate in 24-well dishes, and grown 
under selection in 250μg/ml G418. RKO cells were plated at a density of 5,000 cells per well. 
SW480 cells were plated at a density of 1,000 cells per well. After 21 days, colonies were fixed 
in 4% PFA, stained with crystal violet, and counted. Colony formation was performed in 
triplicate and repeated in three independent transfections. Colony numbers were analyzed 
using a t-test to compare AXIN2 or trAXIN2 transfections to vector-only colony number.  
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Zebrafish embryo injections 
 Zebrafish were bred and maintained in standard conditions under the direction of Dr. 
Anthony Antonellis. The AXIN2 and trAXIN2 cDNAs were cloned into pCSDest using Gateway 
technology (Invitrogen). Messenger RNA was generated using the mMESSAGE mMACHINE kit 
(Abmion). The yolks of one- to two-cell stage embryos were injected with mRNA (~500ng/μl). 
The embryos were monitored up until 48 hours post-fertilization (hpf). The embryos injected 
with trAXIN2 mRNA were only analyzed at 26 or 27-hpf because of the severity of their 
phenotype.  
 
Image quantification 
Relative protein abundance in Western blots was estimated using ImageJ software 
(nih.gov) by comparison to a β-actin loading control band. 
 
Results 
My first step was to address if the 1989G>A allele was a null allele that produced no 
AXIN2 protein. It is possible that this premature stop codon triggers NMD, but there are 
exceptions to the canonical NMD formula. Alternatively, the mutation introduces an AG, which 
could serve a cryptic splice site that could alter splicing and create a new protein product. While 
the sequence change does not predict the introduction of a consensus splice site, I further ruled 
out this possibility by using Spliceport130 (http://spliceport.cbcb.umd.edu/) to analyze the 
genomic DNA sequence of the two alleles from intron 5 to exon 8 (the mutation is in exon 7). 
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The Spliceport analysis found no changes in the predicted splice sites by introduction of the 
1989A allele (See Figure 4.1).  
To address NMD of the 1989G>A transcripts, we examined lymphocytes from the 
Marvin et al. proband79. Peripheral blood lymphocytes (PBLs) were isolated from the whole 
blood and cultured to obtain RNA. NMD is triggered by the pioneering round of translation. To 
enhance transcription and translation of AXIN2, all the PBLs were cultured with BIO, a GSK3β 
inhibitor that activates the expression of Wnt target genes, including AXIN2131 (Appendix B). 
Total RNA and genomic DNA were then isolated from cells and the region immediately 
surrounding the 1989G>A allele was PCR amplified. These bulk PCR products were sequenced 
and TOPO cloned to detect the presence of wild-type and mutant alleles. The 1989G>A allele 
was confirmed in gDNA from the proband, but was absent in gDNA from the DLD-1 cell line 
(Figure 4.2b). Sequencing of the bulk PCR product from cDNA identified the 1989G>A allele in 
roughly equivalent levels to the wild-type allele (Figure4.2c-d). This was true in RNA from PBLs 
that were cultured with or without PHA and IL-2 to enhance lymphocyte proliferation. To 
confirm the presence of the mutant allele, individual TOPO clones were sequenced to genotype 
the 1989 allele and to verify that the 3’UTR of the transcript was present (further ruling out 
plasmid contamination). The ratio of TOPO clones were as follows: 4G:4A in gDNA, 9G:3A in 
cDNA from PBLs, and 6G:4A in cDNA from PBLs treated with BIO. These results suggest that 
many of the 1989G>A transcripts escape NMD and would be free to produce truncated AXIN2 
proteins. Additionally, these results argue against an alternative transcript that uses the G>A 
alteration as a novel splice site. 
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One of the primary functions of AXIN2 is the inhibition of Wnt/β-catenin target genes. 
To test the effect of the trAXIN2 protein on regulation of this function, IEC-6 cells stably 
expressing AXIN2 or trAXIN2 were treated with Wnt3a to activate β-catenin target gene 
expression. RNA was then collected and analyzed by qPCR. As expected, expression of AXIN2 
reduced Wnt target gene expression, but trAXIN2 failed to inhibit Wnt target genes, similar to 
the vector control (Figure 4.3).  
Because trAXIN2 lacks the DIX domain, I hypothesized that the failure to inhibit target 
genes could be due to an inability to dimerize, and therefore the formation of inefficient 
destruction complexes48; 49; 132. To test this hypothesis, differentially tagged AXIN2 constructs 
were co-transfected and the interaction between AXIN2 molecules assessed by 
immunoprecipitation (IP). trAXIN2 interacted with both AXIN2 and trAXIN2 in ratios similar to 
their expression levels (Figure 4.4b). Similar results were seen when AXIN2 was used for IP. 
Because trAXIN2 does not contain the DIX domain, it is most likely that the trAXIN2 interactions 
are not direct, but are facilitated by a protein that contains multiple AXIN binding sites, such as 
APC17. Interactions with AXIN1 were also tested because AXIN1 acts in the β-catenin 
destruction complex and also contains a DIX domain that is used for dimerization with AXIN2 
and other AXIN1 molecules. Interestingly, the AXIN1 interaction with wild-type AXIN2 pulled 
down a greater amount of AXIN2 protein, despite lower AXIN2 protein expression, suggesting 
that the AXIN1:AXIN2 interaction is a direct interaction due to heterodimerization, while the 
AXIN1:trAXIN2 interaction is indirect (Figure 4.4c). Finally, both AXIN2 and trAXIN2 were shown 
to interact with β-catenin, proving that the inhibition of target gene repression is not the result 
of trAXIN2 failing to interact with β-catenin (Figure 4.4c). Overall, these data suggest that 
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trAXIN2 is still capable of assembling in β-catenin destruction complexes, although they may be 
less efficient than wild-type AXIN2 destruction complexes, based on the Wnt-target gene 
inhibition results.  
The trAXIN2 protein was found to be more abundant than wild-type AXIN2, regardless 
of tag, vector backbone or the antibody used to detect it. To rule out a discrepancy in RNA 
levels, cells were transfected with either FLAG-tagged AXIN2 or trAXIN2. Total protein and RNA 
were isolated from the same cell pellets and analyzed by Western blotting and qPCR. No 
significant difference was seen in the abundance of transcripts, while trAXIN2 protein was 
consistently more abundant (Figure 4.5a-b). I next looked at AXIN2 stability by inhibiting the 
proteasome. Inhibition of the proteasome stabilized AXIN2, but the protein did not achieve 
equivalent levels with the trAXIN2 protein (Figure 4.5c). 
The stability of AXIN1 is regulated by GSK3β phosphorylation and PP2A 
dephosphorylation133; 134. The predicted GSK3β phosphorylation sites are conserved between 
AXIN1 and AXIN2 (see Figure 1.2), so presumably, AXIN2 is subject to this same 
phosphorylation-mediated stability whereupon phosphorylated AXIN2 is more stable and 
dephosphorylated AXIN2 is less stable (Figure 4.6a). Additionally, the PP2A interaction domain 
has been mapped to the C-terminus of AXIN1135, so the interaction between PP2A and trAXIN2 
might be disrupted, which could account for the increased stability of the trAXIN2 protein. To 
test the effects of PP2A and GSK3β activity on the AXIN2 and trAXIN2 proteins I used the GSK3β 
inhibitor, BIO, and the PP2A inhibitor, okadaic acid (OA)136. As expected, treatment with BIO 
reduced the levels of AXIN2, while OA increased AXIN2 levels (Figure 4.6b). However, while the 
trAXIN2 protein was stabilized by OA, protein levels were unchanged upon BIO treatment, 
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suggesting that the trAXIN2 protein retains the interaction with PP2A, but does not rely on 
GSK3β phosphorylation to maintain protein stability. Another mode of AXIN2 protein regulation 
is via PARsylation which targets AXIN2 for degradation43. Treatment of cells expressing AXIN2 
and trAXIN2 with a small molecule that inhibits TNKS-mediated PARsylation, XAV939, showed 
that the AXIN2 protein is more sensitive to PARsylation-mediated stabilization than trAXIN2 
(Figure4.6c). 
It has previously been shown that stabilization of AXIN2 inhibits colon cancer cell lines 
with APC mutations43; 69. I tested whether trAXIN2 retains this ability to inhibit the growth or 
survival of colon cancer cell lines in the colony formation assay. I chose the SW480 cell line, 
which has activated Wnt signaling due to APC mutation137, and the RKO cell line with intact Wnt 
signaling138. Like the wild-type protein, trAXIN2 only inhibits colony formation in a cell line that 
is dependent on activated β-catenin signaling (Figure 4.7). In some replicates, the trAXIN2 
protein even seemed better at inhibiting SW480 colony formation, although this is likely due to 
the much higher levels of trAXIN2 protein expression in these cells compared to AXIN2 protein 
levels (Appendix C).  
To assess the function of this truncated protein in vivo, I turned to the zebrafish model. 
The first studies of β-catenin established an important role for the Wnt pathway in 
development, and overexpression of rat Axin2 in Xenopus has been shown to alter the 
dorsal/ventral axis and oppose Wnt-induced axis duplication18. Previous studies have also found 
that the amount of Axin-2 protein must be carefully titrated to achieve normal development in 
the zebrafish (Figure 4.8a)139. To test if the trAXIN2 protein displays a loss of function in vivo, 
one to two-cell stage zebrafish embryos were injected with mRNA encoding either AXIN2 or 
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trAXIN2. First, I confirmed that overexpression of human AXIN2 creates a phenotype similar to 
overexpression of the zebrafish Axin-2, suggesting that the human protein maintains its 
functions in zebrafish cells (Figure 4.8b). Next, I asked if the trAXIN2 mRNA resulted in the same 
phenotype, or a less severe one. I actually found that injection with trAXIN2 mRNA resulted in a 
more severe developmental phenotype (Figure 4.8c), which could be due to higher protein 
levels as was seen in cell culture-based assays. I was unable to measure the relative protein 
levels in the developing embryos, and the severe phenotype made it difficult to address a 
potential mechanism for the difference in phenotype. However, the trAXIN2 zebrafish 
phenotype supports the conclusion that the trAXIN2 protein retains some protein function, or 
potentially acquires new functions.  
 
Discussion 
A germline AXIN2 mutation was found to segregate with an ectodermal dysplasia and 
polyposis phenotype. This mutation is in the same exon as the majority of somatic AXIN2 
mutations reported in cancers85, and may alter AXIN2 mRNA or protein stability.  We studied 
the consequences of this mutation on protein function using the trAXIN2 protein, which lacks 
the DIX domain. This trAXIN2 protein can serve as a model for the truncated AXIN2 proteins 
that potentially result from somatic exon 7 frameshift mutations.  
 The 1989G>A AXIN2 mutation segregates in an autosomal dominant manner79. Whether 
this mutation influences cancer development via a gain-of-function or loss-of-function is not 
understood. If the 1989G>A allele mRNA undergoes nonsense-mediated decay, then it would 
point to a loss-of-function mechanism of disease. This model is consistent with the current 
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belief that AXIN proteins act as tumor suppressors. However, transcripts from both alleles were 
detected in PBLs from a heterozygous individual. Cell culture-based studies suggest that the 
trAXIN2 protein is hypomorphic in Wnt-target gene regulation and more stable than the wild-
type protein. Gross overexpression studies make it difficult to estimate the functional 
consequences of this truncated protein, in vivo, where the expression levels are likely much 
lower. It is conceivable that trAXIN2 could produce less functional destruction complexes, and 
because it is more abundant than wild-type AXIN2, could be sequestering destruction complex 
components away from more efficient AXIN1 or AXIN2 complexes, thereby slowing down the 
turnover of β-catenin, or potentiating the activation of β-catenin by a Wnt ligand.  
This truncated protein was found to have a reduced function in the inhibition of Wnt/β-
catenin target genes, but not because it can’t complex with β-catenin or other AXIN1/2 
molecules. In vitro colony formation studies suggest that the trAXIN2 protein retains the 
functions of the wild-type AXIN2 protein, although in vivo studies using a zebrafish model 
suggested a stronger developmental defect. This apparent disconnect between the reduced 
function and maintained or enhanced/gain of function behavior could be explained by the 
increased stability of the trAXIN2 protein. The inhibition of Wnt target genes was performed in 
cell lines that had been retrovirally transduced to express moderate, and more equivalent, 
levels of the AXIN2 and trAXIN2 proteins. The reduced function in inhibition of Wnt target 
genes suggests that the trAXIN2 protein could be hypomorphic. The zebrafish and colony 
formation assays were performed with gross, transient over-expression; therefore, the higher 
trAXIN2 protein levels in these studies could compensate for a reduced functionality. 
Additionally, while the inhibition of colony formation was only significant in a CRC cell line with 
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mutant APC, it’s possible that AXIN2 and trAXIN2 exert their inhibitory effects via a non-β-
catenin dependent mechanism. The trAXIN2 protein could indeed have a reduced function in 
the inhibition of Wnt-target genes, but still retain functions in non-canonical pathways such as 
the ERK56 or JNK pathways58, or by regulation of GSK3β51. 
The observed difference in the level of AXIN2 and trAXIN2 proteins suggest that there is 
a functional difference in the two proteins. This could be due to a difference in the regulation of 
protein stability, as suggested by the differential stabilization by GSK3β, but it is also possible 
that higher levels of the wild-type protein simply aren’t tolerated by the cell because they 
inhibit growth or survival. Preliminary flow cytometry data in 293T cells using fluorescently-
tagged AXIN2 and trAXIN2 constructs saw no clear sub-G1 peak to indicate the induction of 
apoptosis (Appendix D), although further studies at different time-points will be needed to 
clarify if cells expressing high levels of AXIN2 are indeed lost to apoptosis or a cell cycle arrest. 
There are likely multiple cellular pathways involved, but the exact mechanism(s) for why the 
truncated protein accumulates to such levels remains unclear. 
It is important to also consider the possibility that the trAXIN2 protein has a gain-of-
function effect in cells. Some publications have suggested that in certain contexts, AXIN2 can 
promote tumor invasion and progression50; 51. One proposed mode of AXIN2-mediated tumor 
invasion is via the kinase GSK3β51. Overexpression of AXIN2 has been shown to alter the nuclear 
to cytoplasmic ratio of GSK3β, influencing the expression of genes involved in the epithelial to 
mesenchymal transition51. A more stable trAXIN2 protein could recreate the situation of AXIN2 
overexpression and exert broader effects via GSK3β. Another argument against this human 
allele being a simple loss of function or null allele is that the Axin2 knockout mouse has no 
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reported cancer phenotype38. To further address the function of this allele, a knock-in mouse 
model of the 1989G>A allele has been created and ongoing studies will address mRNA stability 
and protein function in vivo.  
As negative regulators of Wnt signaling, AXINs promote the assembly of complexes that 
target β-catenin for degradation. The AXINs are considered to be tumor suppressors because of 
this ability to inhibit β-catenin, although the clinical evidence to support their role in cancer is 
limited. Interestingly, AXIN2 is a β-catenin/TCF target gene and is actually up-regulated in many 
cancers with activating Wnt pathway mutations39; 40; therefore, it is important to understand 
what role wild-type or truncated AXIN2 protein products may play in cancer development or 
progression.  
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Figure 4.1- The 1989G>A allele does not introduce a cryptic splice site 
(A) Consensus splice acceptor and donor sequences are shown with the AXIN2 genomic DNA 
sequence for the G and A alleles. (B) Spliceport prediction for the AXIN2 1989G or 1989A 
genomic DNA shows no change in the predicted splice sites. 
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Figure 4.2- Transcripts from the 1989G>A allele escape NMD 
(A) Genomic DNA was PCR amplified to identify the 1989 allele(s) present in cells. 
Chromatograms confirming the absence of the A allele in a wild-type cell line, and of the GA 
genotype in the proband’s cells. (B) cDNA isolated from a heterozygous carrier (the proband) 
was amplified by PCR to determine which transcripts are expressed in PBLs. Sequencing results 
of bulk PCR products identifies transcripts from both the G and A alleles. Individual TOPO clones 
were cloned from bulk PCR products and also sequenced, the results of which are shown below 
the chromatograms. 
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Figure 4.3- Wnt target gene inhibition 
(A) IEC-6 cells were transduced with either vector, AXIN2 or trAXIN2 expression constructs to 
create cell lines that stably express the full-length and truncated AXIN2 proteins. (B) Stable 
transductants were treated with 200ng/ml Wnt3a to induce target gene expression. After 16 
hours, RNA was collected and target genes measured by qPCR. Panel B is a representative 
experiment. 
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Figure 4.4- The trAXIN2 protein retains destruction complex associations 
293T cells were transfected with various expression constructs to test protein interactions. (A) 
Input (20μg) for AXIN2, trAXIN2 homodimerization analysis. (B-C) Immunoprecipitation 
experiments show that trAXIN2 interacts with trAXIN2, AXIN2, AXIN1 and β-catenin. 
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Figure 4.5- trAXIN2 protein and transcript levels do not correlate 
(A) Western blot of 293T cells transfected with AXIN2 or trAXIN2 expression constructs. Relative 
protein level was quantified using ImgaeJ. (B) Quantification of AXIN2 transcripts by qPCR 
shows that trAXIN2 protein levels are not solely a reflection of transcript levels. (C) Proteasome 
inhibition of DLD-1 cells expressing AXIN2 or trAXIN2 with MG132 stabilizes AXIN2, but not to 
the level of trAXIN2 protein.  
  
  61 
 
 
 
Figure 4.6- trAXIN2 stability is not GSK3-β dependent and does not respond to XAV treatment 
(A) Diagram of the regulation of AXIN phosphorylation by GSKβ and PP2A. (B) Treatment of 
293T cells expressing full-length or truncated AXIN2 proteins with 1μM BIO and 100nM Okadaic 
Acid (OA) shows a differential stabilization by GSK3β-inhibtion. Quantification of AXIN2 protein 
levels is shown in relation to the β-actin loading control. A Western blot of phospho-β-catenin is 
included as a control for OA activity.  (C) Treatment with the TNKS inhibitor, XAV939, stabilizes 
AXIN2 to a greater extent than trAXIN2 protein.  
BIO 
OA 
T 
T 
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Figure 4.7- AXIN2 and trAXIN2 inhibit colony formation in Wnt-dependent colon cancer cells 
Drug-resistant colony formation assays in SW480 (A-C), and RKO (D-F). Similar to AXIN2, 
trAXIN2 expression inhibits colony formation in SW480 cells, which have aberrantly activated 
Wnt/β-catenin signaling, but not in RKO cells, which have intact Wnt/β-catenin signaling. 
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 GARS RNA (25:5:0) AXIN2 RNA (14:39:1)  trAXIN2 (6:13:30) 
 
Figure 4.8- AXIN2 and trAXIN2 produce a developmental phenotype in zebrafish 
(A) Previously published work showed that over-expression and knockdown of zebrafish Axin-2 
causes a developmental phenotype. (B) Ectopic expression of human AXIN2 results in a 
developmental phenotype similar to zebrafish Axin-2. (C) Developmental phenotypes of 
zebrafish embryos 27hpf show that trAXIN2 produces a more severe developmental phenotype. 
Quantification of phenotypes shown below (wild-type: altered body plan: severely stunted).
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Chapter 5: The role of Axin2 in a mouse model of colon cancer 
 
Abstract 
In order to further explore the significance of the 1989G>A truncating mutation in 
disease, it is necessary to more properly define the role of wild-type AXIN2 under normal 
physiological conditions. If the AXIN2 protein indeed acts as a tumor suppressor, this could help 
inform predictions of loss-of-function vs. gain-of-function mechanisms. Ongoing studies with a 
mouse model of the Axin2-null allele aim to determine how loss of AXIN2 might alter normal 
colon epithelial development or contribute to cancer progression. Additionally, although RNA 
studies in the proband’s PBLs suggests otherwise, if the 1989G>A allele is a null allele, this 
mouse model would be an appropriate model for the constitutional loss of one allele of Axin2. 
Studies of these Axin2 mice found that mice with one or no functional Axin2 alleles have normal 
teeth. Analysis of colon tissues in a preliminary cohort found no change in proliferation across 
genotypes, but in liver tissue, some Wnt target genes were elevated with loss of Axin2. Using a 
mouse model of colon cancer, I am also testing whether loss of Axin2 enhances the tumorigenic 
phenotype, a result that could support AXIN2 as a tumor suppressor in CRC. While the tumor-
based studies are still ongoing, the first cohorts of Apcfl/fl mice suggest that Axin2 genotype has 
no effect on survival, but may have more subtle influences on proliferation or the distribution 
of adenomas in the colon. 
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Introduction 
Mutations in the APC tumor suppressor gene are found in approximately 80% of human 
CRCs and germline mutations in APC underlie the hereditary CRC syndrome FAP11; 12; 63; 137; 140. 
The Fearon lab previously developed a mouse model of colorectal cancer using a floxed (fl) Apc 
allele141 and a Tamoxifen-inducible Cdx2-Cre (Cdx2P-CreERT2)142. This model restricts the 
expression of Cre recombinase to caudal embryonic tissues and to the epithelium of the distal 
ileum, cecum, colon, and rectum in the adult mouse, with the strongest induction of Cre activity 
occurring in the cecum and proximal colon (Appendix D). Cdx2P-CreERT2, Apcfl/fl mice rapidly 
develop adenomas following intraperitoneal (IP) injection with Tamoxifen (TAM) and become 
moribund in 20-30 days.  
Interestingly, AXIN2 itself is a -catenin/TCF target gene and is up-regulated in cancers 
with activating Wnt pathway mutations39; 40. In the context of the germline mutations 
associated with oligodontia/CRC predisposition, it is important to better understand what role 
the wild-type AXIN2 protein may play in cancer development or progression in order to further 
explore the functional significance of germline and somatic truncating mutations. AXIN2 is 
hypothesized to be a tumor suppressor in CRC and studies with a small molecule that stabilizes 
both AXIN1 and AXIN2 found that increased AXIN protein levels reduced the number and size of 
tumors in an Apc-dependent model of CRC69.  However, some reports suggest that high levels 
of AXIN2 protein may actually promote invasive and metastatic phenotypes in cancer cells as 
seen in tissue culture and mouse xenograft experiments50; 51. To test the hypothesis that AXIN2 
acts as a tumor suppressor in CRC, mice carrying an Axin2-null allele, Axin2LacZ, were crossed to 
  66 
the Cdx2P-CreERT2 mouse model of Apc-dependent colon cancer to ask whether loss of Axin2 
modifies the Apc tumor phenotype.  
 
Materials and Methods 
Mouse Models and Tamoxifen Treatment 
An Axin2LacZ mouse was obtained from The Jackson Laboratory on a C57BL/6 
background (stock number: 009120) and bred to C57BL/6 mice to generate a colony of Axin2LacZ 
mice. These mice were then bred to our floxed Apc tumor model to create Apcfl/fl, Cdx2P-
CreERT2 mice with varying Axin2 genotypes. Mice were aged to at least three months and then 
injected with 150μl of TAM (Sigma-Aldrich) on two consecutive days. Injections were delivered 
IP with 20mg/ml TAM dissolved in corn oil. The mice were then monitored daily and euthanized 
at 15 days post TAM treatment or when they appeared moribund. One hour prior to 
euthanization, the mice received an IP injection of 100μl of 10mg/ml BrdU. All animal care and 
experimental procedures were performed in compliance with the guidelines set by the 
University of Michigan’s University Committee on Use and Care of Animals.  
 
Analysis of teeth 
The teeth of six Apc fl/fl, Axin2LacZ/LacZ mice; two Apc fl/fl, Axin2LacZ/+ mice; two Apc fl/fl, 
Axin2+/+ mice; and two Axin2LacZ/LacZ mice were examined by eye for enamel coloration, incisor 
shape and size, and the number of upper and lower molars. 
 
Immunohistochemistry 
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 Tissues were fixed overnight in 10% buffered formalin, processed, embedded in 
paraffin, and 5μM sections cut. Slides were stained with H&E and BrdU (BrdU antibody from BD 
Pharmigen). Tissues were stained for BrdU using the Vector Labs M.O.M. (Mouse on mouse) 
and DAB kits. Briefly, the BrdU staining protocol is as follows. Slides were baked at 58˚C and 
then rehydrated in xylenes and a gradient of ethanol. Antigen retrieval was done Citra Plus 
buffer (BioGenex) and slides were incubated in 2N HCl at 37˚C for 30 minutes and then 
endogenous peroxidase activity was quenched by incubation in 80%MeOH/ 3%H2O2 for 20 
minutes. BrdU antibody was used at a concentration of 1:400 following the M.O.M. and DAB 
published protocols with the modification of an overnight incubation at 4˚C with the primary 
antibody. The number of BrdU positive cells were counted using ImageJ software (nih.gov). 
 
RNA isolation 
RNA was isolated by homogenizing tissues in Trizol followed by RNA isolation. RT-PCR 
using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) was used to 
synthesize cDNA and gene expression was analyzed by qPCR. The primers used for qPCR are 
shown in the table below. 
Table 5.1- qPCR primers for Wnt target genes 
Gene Sequence 
-actin F- GCCTTCCTTCTTGGGTATGG 
R- GCCTGGGTACATGGTGGT 
Axin2 F- GAGGATGCTGAAGGCTCAAA 
R- GCAGGCAAATTCGTCACTC 
Lgr5 F- GGAATAAAGACGACGGCAAC 
R- GGATCAGCCAGCTACCAAA 
Irs1 F- GACGCTCCAGTGAGGATTT 
R- AGGTCCTGGTTGTGAATTGTG  
Nkd1 F- CCGAGCAGACACCAAACC 
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R- TCCTCTCAATGTTCTCATCCA 
 
 
Results 
I began by analyzing the Axin2 mice under normal conditions. Mice carrying the Axin2LacZ 
allele were aged to 6 months and then the colon and intestine were collected from each mouse 
for tissue analysis, as well as a sample of the liver, a tissue with high expression of Axin2 
protein, for RNA analysis. I found that without exogenous stimulation, the expression of some 
Wnt target genes is elevated in the liver tissue of mice with loss of Axin2 (Axin2LacZ/ LacZ 
genotype) (Figure 5.1). This finding sets the stage for tissues that could be primed for Wnt 
activation, or that could display a potentiated response to Wnt stimulation as previously seen in 
mouse mammary stem cells53. 
Wnt signaling is activated at the base of colon crypts143 and Wnt signaling is essential for 
normal colon epithelial cell proliferation144. As a negative regulator and feedback repressor of 
Wnt signaling, Axin2 could be playing an important role in the maintenance of Wnt signaling in 
the colon, and loss of Axin2 protein could alter the distribution of Wnt signaling, skew the 
differentiation pattern of colon epithelial cells, or change the number of proliferating cells145. 
To assess the impact of loss of Axin2 on proliferation, I analyzed the number of BrdU positive 
cells in the proximal and distal colon of these mice (Figure 5.2, Table 5.2). From this first small 
cohort, it is not clear that a change in the levels of Axin2 protein influences proliferation in the 
colon. Analysis of more mice is ongoing.  Finally, because the family carrying the 1989G>A allele 
has oligodontia, I examined the teeth of the Axin2LacZ/LacZ mice and Apc fl/fl, Axin2LacZ/LacZ mice 
but found no abnormalites in the shape of their incisors or the number of molars (Figure 5.3). 
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To assess the consequence of loss of Axin2 on the Apc tumor phenotype, three mice of 
each Axin2 genotype (wild-type, heterozygous, or homozygous for the LacZ allele) were 
injected with two consecutive doses of TAM and monitored for 15 days at which time the mice 
were euthanized and their tissues collected for analysis. One Axin2LacZ/LacZ mouse was 
euthanized on day 14 at the request of the University Laboratory Animal Medicine team 
(ULAM). His paired littermates were also euthanized at this time point. While two of the three 
Axin2LacZ/LacZ mice appeared ill and were flagged by ULAM for rapid weight loss within the first 
eight days post-TAM injection, the other genotypes appeared moderately healthy at the 15-day 
euthanization time point. Colon tissues from these mice were analyzed for β-catenin 
localization and proliferation via BrdU staining. However, while the colon tissues displayed 
hyperplasia and increased crypt height, there were few adenomatous areas and little nuclear β-
catenin staining.  
The Axin2LacZ/LacZ mice are frequently flagged for their small size and altered body 
stature, so the study was repeated with a second cohort, using both Cre-positive and Cre-
negative mice to assess whether the weight loss seen in the Axin2LacZ homozygous mice was 
specific to their genotype, and if it would impair survival for tumor studies. These mice were 
injected with the same two-dose TAM scheme and then weighed daily and monitored until they 
became moribund. In this small cohort, TAM injection caused a uniform loss in weight 
regardless of Axin2 or Cre genotype, and all mice recovered from the TAM-induced weight loss 
until becoming moribund (Figure 5.4). Unlike the first cohort of mice, we saw adenomas and 
nuclear β-catenin staining in all Cre-positive mice. This second cohort survived longer than 
expected, although a new batch of Tamoxifen was used, so there could be lot to lot variation in 
  70 
the potency of the drug. All the subsequent studies of these mice used this same, second batch 
of Tamoxifen to maintain consistency.   
A final, third cohort with two mice of each Axin2 genotype was injected with the same 
two-dose scheme and monitored until moribund. In examining these mice along with the 
second cohort, there was no significant change in survival (Table 5.3), although there did 
appear to be a possible difference in the gross physiology of the mice based on Axin2 genotype. 
The usual phenotype seen in Apcfl/fl, Cdx2P-CreERT2 mice is hyperproliferation of the cecum and 
proximal colon with polyposis present in the proximal to upper middle colon with few distal 
alterations. Loss of Axin2 appeared to potentially reduce hyperproliferation and polyposis in the 
proximal colon, and to shift the adenoma phenotype more distally (Figure 5.5). There also 
appeared to be an increase in the number of lymphoid cells seen in the Axin2LacZ/LacZ mice, 
although the cohort size is small and further histological analysis of these mice is ongoing. 
 
Discussion 
The truncating germline AXIN2 mutations reported in CRC predisposition syndromes 
could be null or loss of function alleles, in which case, the Axin2LacZ/+ mouse could model the 
developmental and tumorigenic effects of these alleles.  Additionally, the Axin2LacZ/LacZ mouse 
could model the loss of the second AXIN2 allele during cancer development, if AXIN2 adheres to 
a traditional two-hit tumor suppressor model. The two families with germline, truncating AXIN2 
mutations have oligodontia, a phenotype that was not seen in the Axin2LacZ mice, but this does 
not prove that the oligodontia is unrelated to an AXIN2 mutation, or that the AXIN2 mutation is 
not a loss-of-function. Missense mutations in AXIN2 have been linked to oligodontia123; 146; 147 
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and assessment of the oligodontia phenotype in mice is complicated by the differences in 
mouse and human dentition. Humans have two stages of dentition, and the defect in the 
1989G>A individuals is in the second dentition (permanent teeth). Mice, on the other hand, 
have only one stage of dentition and a pair of continuously growing incisors, neither of which is 
an accurate recapitulation of human secondary dentition. 
The colon epithelium of Axin2LacZ/+ and Axin2LacZ/LacZ does not appear grossly different 
than in wild-type mice and no difference in proliferation was seen as evidenced by BrdU 
staining. Some Wnt target genes were found to be elevated in the liver, a tissue that expresses 
AXIN2 protein under normal conditions, suggesting that there are potentially differences in Wnt 
activity in colon tissue as well. AXIN2 is one of many feedback repressors of Wnt signaling, and 
if Wnt signaling is elevated at baseline, then it could “prime” the cells, making them more 
susceptible to a pro-oncogenic hit. Further histological analysis of the cell lineages present in 
the colon of these mice will ask if there are any developmental defects due to this difference in 
Wnt regulation, as an activation of Wnt activity has been shown to alter differentiation, 
survival, migration, and proliferation in the intestine148. The analysis of tumor studies with mice 
on the Apcfl/fl background is still underway, but the data thus far suggests that there is no 
difference in survival although there may be a shift in the hyperproliferation and adenomatous 
phenotype toward the distal end of the colon, which matches the gradient of Axin2 expression 
in the mouse intestine and colon. It is possible that the impact of a change in Axin2 protein 
level cannot be observed in this mouse model because the loss of both Apc alleles creates such 
a severe distortion of Wnt signaling, or because the defects in Axin2 are redundant to Apc and 
would only impact cancer progression in the absence of other Wnt pathway abrogation. To 
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address this issue, I am also testing the Axin2 mice in a heterozygous Apc background and in a 
Kras hyperplasia model (see Chapter 6). Two families have been reported to have a colorectal 
cancer syndrome including oligodontia that is associated with a germline truncating mutation in 
AXIN2. The mechanism by which this mutation predisposes to colon cancer remains unclear. 
Mice lacking one or two copies of Axin2 display no tooth phenotype, but loss of Axin2 may 
enhance baseline Wnt signaling and alter the distribution of the hyperplasia/adenoma 
phenotype seen in Apcfl/fl mice. Further studies with a knock-in mouse model of one of the 
human mutations, and looking at the role of Axin2 in other models of CRC could clarify the role 
AXIN2 plays in cancer predisposition.  
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Figure 5.1- Expression of some Wnt target genes is elevated in Axin2LacZ mouse liver tissue 
Wnt/β-catenin target gene expression in liver tissue was measured by qPCR. Data are shown as 
the average of two mice per genotype ± standard deviation. 
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Proximal Colon 
 Axin2+/+ Axin2LacZ/+ Axin2LacZ/LacZ 
 
 
Distal Colon 
 Axin2+/+ Axin2LacZ/+ Axin2LacZ/LacZ 
 
 
Figure 5.2- BrdU staining to measure proliferation in the colon of Axin2LacZ mice 
Tissue sections of the proximal and distal colons of six month old mice were stained for BrdU 
positive cells. A quantification of the staining is shown in Table 5.2.    
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Table 5.2- Quantification of BrdU-positive cells in the colon of Axin2LacZ mice 
 
  
Genotype
Number of crypts 
counted
Total number of 
BrdU+ cells
BrdU+ cells per 
crypt
Axin2 +/+ 42 424 10.1
Axin2 +/+ 23 160 7.0
Axin2 LacZ/+ 33 189 5.7
Axin2 LacZ/+ 25 208 8.3
Axin2 LacZ/LacZ 34 295 8.7
Axin2 LacZ/LacZ 44 278 6.3
Axin2 +/+ 19 109 5.7
Axin2 +/+ 47 255 5.4
Axin2 LacZ/+ 44 330 7.5
Axin2 LacZ/+ 59 360 6.1
Axin2 LacZ/LacZ 37 179 4.8
Axin2 LacZ/LacZ 50 338 6.8
P
ro
xi
m
al
 c
o
lo
n
D
is
ta
l c
o
lo
n
 
  76 
 
 
Figure 5.3- Analysis of the tooth phenotype in Axin2LacZ mice 
(A) A close-up image identifying the three lower molars and proper yellow shade indicating 
enamel on the incisors. (B) Sample side-by-side comparison of Apcfl/fl mice shows no significant 
difference in the size or shape of the incisors.   
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Figure 5.4- Analysis of weight loss in Apcfl/fl, Axin2LacZ mice 
Following two doses of TAM, mice were monitored and weighed daily until becoming 
moribund. Cre-negative mice were euthanized with their Cre-positive littermates. Of note, the 
Cre-positive Axin2LacZ/+ mouse was male, while the Axin2+/+ and Axin2LacZ/LacZ mice were females. 
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Table 5.3- Survival statistics of Apcfl/fl mice  
Ear tag Sex Axin2 Age @ inj. Days post-inj.  
SM-34 F +/+ 149 31  
SM-55 M +/+ 201 28  
SM-112 F +/+ 118 32 30 ± 2 days 
SM-35 M lacZ/+ 149 27  
SM-57 F lacZ/+ 201 29  
SM-111 F lacZ/+ 118 47 34 ± 11 days 
SM-40 F lacZ/lacZ 149 31  
SM-53 M lacZ/lacZ 215 29  
SM-90 M lacZ/lacZ 153 22* 27 ± 5 days 
 
*This mouse was euthanized at 22 days at the request of ULAM because of anemia 
Mean survival ± standard deviation.  
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Apcfl/fl, Axin2+/+  
 
Apcfl/fl, Axin2LacZ/+  
 
Apcfl/fl, Axin2LacZ/LacZ  
 
 
Figure 5.5- Gross colon phenotype of Apcfl/fl mice post-TAM treatment 
After two doses of TAM, mice were followed until moribund. Tissues were collected, fixed, and 
photographed. Colon images from three cohorts of mice show the thinner proximal colon tissue 
and perhaps greater distal involvement in the Axin2LacZ/+ and Axin2LacZ/LacZ mice.  
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Chapter 6: Conclusions 
 
Summary of findings 
The Wnt pathway has essential roles in development, differentiation, and maintenance 
of cellular homeostasis4. In the canonical Wnt pathway, activating Wnt ligands stabilize β-
catenin, freeing it to translocate to the nucleus where it activates expression of β-catenin/TCF 
target genes. Somatic mutations that constitutively stabilize β-catenin are found in many 
cancers, including about 90% of colorectal cancers. Many issues regarding Wnt signaling in 
cancer remain unresolved, and genetic and cell-based studies may offer important insights. In 
my thesis work, I have sought to clarify the role that AXIN2, one of the proteins involved in 
regulation of β-catenin/Wnt-signaling, potentially plays in cancer.  
Analysis of PBLs from an individual heterozygous for the 1989G>A allele shows that 
transcripts from both the A and G allele are present in roughly equal amounts, suggesting that 
this transcript escapes NMD and can encode a truncated protein. Testing of this truncated 
protein in vitro found that the trAXIN2 protein can still interact with destruction complex 
proteins, including β-catenin and other AXIN1/2 molecules. Additionally, the trAXIN2 protein 
retains function in the inhibition of colony formation in a Wnt-dependent CRC cell line. 
However, the trAXIN2 protein in stable cell lines, has reduced function in the inhibition of Wnt 
target genes, suggesting that this allele could be hypomorphic. The trAXIN2 protein was also 
found to be more abundant, presumably more stable, than wild-type protein and this increased 
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protein level could account for the equivalent colony inhibition and zebrafish developmental 
phenotype, even if the allele is hypomorphic. Finally, the trAXIN2 protein stability was found to 
be regulated by PP2A, but inhibition of TNKS1/2 and GSK3β had minimal effect on protein 
levels. This difference in the regulation of protein levels points to a functional difference 
between the trAXIN2 and AXIN2 proteins, but the exact mechanism needs further investigation.  
Overall, this data supports the conclusion that the 1989G>A allele is neither a null allele 
nor a complete loss of function. Rather, this allele appears to be hypormorphic in the inhibition 
of Wnt/β-catenin signaling. It is also possible that other non-canonical protein interactions have 
been disrupted, creating loss-of-function phenotypes; or the trAXIN2 protein could acquire 
novel protein interactions or traits, creating a gain-of-function phenotype. The increased 
protein stability could be due to either a gain or loss of some protein interaction, but with more 
trAXIN2 protein in the cell hypomorphic actions could be masked, or gain-of-function actions 
amplified. Additionally, with more trAXIN2 in a cell, β-catenin destructions complex 
components may be tied up with a more abundant, but less functional version of AXIN2, 
perhaps slowing the turnover of β-catenin and delaying negative feedback repression. 
 
Significance 
Individuals carrying the 1989G>A allele have a predisposition to colon cancer. AXIN1 and 
AXIN2 mutations have been reported in a subset of many cancers, but clear functional evidence 
to support the role of these two proteins as tumor suppressors in CRC is lacking. In addition to 
creating a better understanding of the truncating germline and somatic mutations reported in 
association with CRC, it is important to clarify the role of AXIN2 in cancer. The role of AXIN2 in 
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promoting or suppressing cancer is debated; therefore, a better understanding of the role of 
the protein, and mutant forms of the protein, in normal and cancer contexts will be key for 
determining if AXIN proteins are an appropriate therapeutic target.  
 
Ongoing work 
Axin2 modification of the Apc tumor phenotype 
 While I am completing analysis of the inducible Apc homozygous mice, I have also been 
ageing mice that have a constitutional Apc defect141. Similar to the Cdx2P-CreERT2mice, these 
Cdx2P-NLS Cre mice express a Cre recombinase specifically in the caudal portion of the body, 
but rather than being inducible, the NLS Cre transgene is constitutive. Cdx2P-NLS Cre, Apcfl/+ 
mice develop disease more distally than other mouse models of CRC and they survive for 
approximately 200 days of age with a sex-specific difference in survival141. Because the 
tumorigenic effects of Axin2 may act via the Wnt signaling pathway, and because the Apcfl/fl 
tumor phenotype develops so rapidly, the heterozygous state might allow us to observe more 
subtle changes caused by changes in Axin2 protein levels.  
 The findings of a recent study of Sessile Serrated Adenomas suggested that a decrease 
in AXIN2 expression correlates with smaller, more distal adenomas92. While Sessile Serrated 
Adenomas are more associated with BRAF and KRAS mutations, it will be interesting to see if 
we find similar changes in phenotype as we continue to analyze our Apc-dependent CRC model.  
 
Knock-in analysis and rescue 
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 In order to answer, in vivo, what is the significance of the 1989G>A allele, I have 
generated a knock-in mouse of the human allele. Because I have been unable to prove if the 
1989G>A allele is a loss of function allele or if it has some altered function, studies in the mouse 
will be highly valuable. These mice will be examined for an ectodermal phenotype (alterations 
in teeth or hair) and for a colon phenotype to determine if the 1989G>A allele affects colon 
epithelial development or changes the steady state of Wnt signaling or proliferation. Crossing 
these mice to the Apc heterozygous background or a Kras background to sensitize them will 
help determine if the colon epithelium in these mice is predisposed to developing adenomas. 
Finally, these mice can be crossed to the Axin2LacZ mice to test if one or two copies of the 
1989G>A allele is sufficient to rescue the Axin2-null phenotype, perhaps answering whether 
this allele is hypomorphic. 
 
Future directions 
AXIN2 protein interactions required for Wnt signal transduction 
I have shown that trAXIN2 still interacts with other AXIN molecules and β-catenin, but to 
further understand the impact of the trAXIN2 protein, I would test if the protein retains 
interactions known to be important for the transduction of a Wnt signal. A recent study on the 
conformation of AXIN proteins suggests that the protein auto-regulates its function via an 
interaction between the N- and C-termini of the protein that renders the protein in a “closed” 
conformation149. A Wnt-responsive luciferase screen identified a small molecule that 
potentiated stimulation with a Wnt ligand. It was found that this small molecule binds to the 
AXIN1 DIX domain and prevents the self-interaction between the N- and C-termini of the 
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protein. Without this interaction, the protein is always in the “open” conformation, with 
increased affinity for LRP5/6 binding. This means that “open” AXIN1 localizes to the membrane, 
rather than to β-catenin destruction complexes, increasing the levels of nuclear β-catenin and 
Wnt target gene expression149. It has been previously found that the AXIN/LRP interaction is 
necessary for Wnt signal transduction29; 150, and concordantly, the authors saw a stabilization of 
β-catenin and an increase in Wnt target genes, although only in response to a Wnt ligand, not 
at steady state149. The authors went on to show that an AXIN1 protein lacking the N-terminal 
domain has a higher affinity for LRP5/6 binding149. The authors propose that the transition of 
AXIN1 from “closed” to “open” is kinetically difficult, but that this small molecule, or loss of the 
interacting regions of the AXIN1 protein create a kinetically favorable “open” configuration that 
has a higher affinity for LRP binding and can thus activate or potentiate Wnt signaling149. The 
authors only tested a ∆N-AXIN1 protein, not a ∆C-AXIN1 protein, but it is possible that ∆C-
AXIN1 would similarly reside in the “open” conformation and potentiate Wnt signaling.  
While most of the studies of Wnt signal transduction has been completed with AXIN1, it 
is predictable that these functions could extend to the AXIN2 or trAXIN2 protein, so I would 
propose to test the interaction of AXIN2 and trAXIN2 with LRP5/6 and DVL, another protein 
important for the Wnt membrane signalsome77. These interactions could provide useful insights 
because the DVL protein interacts via the DIX domain77; 132, which is missing in trAXIN2, and the 
LRP-interaction domain has been mapped to C-terminal half of the AXIN1 protein151, so it is 
possible that trAXIN2 does not interact with LRP or DVL, which could have functional 
consequences for Wnt signal transduction.  
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AXIN2 as an oncogene: the Axin2 Canp allele 
I have begun to ask how the dose of Axin2 alters the tumor phenotype in a mouse 
model of colon cancer, but we are only looking at loss of Axin2, never gain. I propose to study 
the Axin2canp allele to model the impact of increased dosage Axin2 on tumor development. 
While homozygotes for the Axin2canp allele are lethal, heterozygotes are viable and rescue the 
Axin2-null phenotype152. Analysis of this allele in a CRC or other mouse models of cancer could 
help clarify if there is a role for AXIN2 in promoting cancer progression, invasion, or metastasis. 
Studies with this allele would be additionally helpful because the canp allele is stabilized by a 
disruption of the interaction with TNKS1/2152, so this allele is a genetic model that could 
support or discourage pharmacological intervention with Tankyrase inhibitors. 
 
AXIN2 and non-canonical signaling  
Studies of AXIN2 in the context of APC mutation might hide Wnt pathway effects or 
complicate analysis because of the already activated Wnt/β-catenin signaling. The AXIN 
proteins have been previously reported to be involved in a multiple non-canonical signaling 
pathways including the Ras/ERK56; 57 and SAPK/JNK pathways58, so it is valuable to examine if 
trAXIN2 or loss of AXIN2 alters these interactions. To address this, I will test the effect of AXIN2 
and trAXIN2 on Ras stability and signaling in cell lines and in our knock-in mouse model. 
Furthermore, I propose to use a Kras model of intestinal hyperplasia153 to investigate whether 
loss or gain of Axin2 protein (or mutation via 1989G>A) promotes the progression of Kras-
mediated hyperplasia to the adenoma stage, perhaps by a cooperative Wnt pathway activation, 
or via regulation of Kras.   
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Work to address the functional significance of Axin1 protein domains in the mouse 
model found that both the RGS domain and the six C-terminal amino acids (C6) of Axin1 are 
necessary for normal mouse development154. Mice homozygous for mutations that deleted the 
RGS or C6 domain of the Axin1 protein had an embryonic lethal phenotype similar to the Axin1-
null phenotype. The C6 domain has been implicated in the activation of JNK signaling155, and it 
is known that the C6 domain is the site of a SUMO modification that stabilizes AXIN1156. 
Interestingly, the ∆C6 homozygous ES cells had no detectable Axin1 protein, although the 
mRNA levels were equivalent to wild-type. Furthermore, the embryonic lethality was partially 
rescued by loss of one allele of Ctnnb1, suggesting that the lethal phenotype is, in part, due to 
over-activation of Wnt signaling154. The C6 domain of Axin1 is conserved in human AXIN1 and 
AXIN2, so I propose to ask whether AXIN2 similarly activates the JNK signaling pathway, and if 
so, whether the trAXIN2 protein, which lacks the C6 domain, has any effect on JNK signaling. I 
would predict that the trAXIN2 protein does not affect JNK signaling, as C-terminal deletions in 
AXIN1 had reduced function in JNK signaling assays58.  
Finally, to address the importance of AXIN2 function outside the canonical Wnt 
pathway, I would cross the Axin2LacZ/LacZ mouse to a mouse with only one allele of β-catenin to 
determine if this rescues the Axin2-null phenotype. The importance of the AXIN proteins in 
non-canonical signaling and whether these pathways are activated via effects on β-catenin 
protein levels is unclear. Analysis of this cross could begin to answer these questions, and to 
determine whether β-catenin-dependent, or non-canonical roles are the key to AXIN2’s 
functional significance in development and cancer. 
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In summary, the AXIN proteins play an established role in the inhibition of β-catenin 
dependent Wnt signaling and individuals with germline, truncating mutations in AXIN2 have a 
predisposition to CRC. Additionally, the AXIN proteins have been proposed as therapeutic 
targets in cancer. Many questions remain about AXIN1 and AXIN2 under normal physiological 
conditions, and in cancer development, but further molecular experiments and mouse models 
can clarify the function and value of these proteins.  
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Appendices 
 
Appendix A- Table of CRC mutations identified in Wnt pathway components 
(Adapted from the TCGA dataset on human colon and rectal cancer mutations63) 
 
Gene 
Frequency in 
non-HM CRCs 
Frequency in       
HM CRCs 
DKK1-4 4% 33% 
LRP5 <1% 10% 
FZD10 19% 13% 
FAM123B 7% 37% 
AXIN2 4% 23% 
APC 81% 53% 
CTNNB1 5% 7% 
TCF7L2 12% 30% 
SOX9 4% 7% 
FBXW7 10% 43% 
ARID1A 5% 37% 
Total 92% 97% 
 
non-HM, non-hypermutated 
HM, hypermutated 
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Appendix B- BIO induction of AXIN2 expression in PBLs and the T-ALL cell line, SUPT-1 
Target gene expression in cell populations treated with DMSO or BIO. (A) PBLs (Suspension) and 
PBMCs (Adherent) were treated with BIO to induce Wnt target genes, namely AXIN2. (B) The T-
ALL cell line SUP-T1 was used to as a positive control for CD3 expression to confirm that the 
isolated cells were indeed lymphocytes. 
 
A 
 
 
 
B 
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Appendix C- Western blot of AXIN2, trAXIN2 expression in SW-480 cells 
SW-480 cells were transfected with expression vectors as indicated, counted and plated for 
drug-resistant colony formation. The remaining cells were grown under selection for 14 days 
and then lysed for Western blotting. Note the strong expression of trAXIN2. 
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Appendix D- Flow cytometric analysis of cells expressing AXIN2 or trAXIN2 show no significant 
inhibition of proliferation or cell survival. 
293T cells were transfected with eYFP-tagged AXIN2, trAXIN2 or vector constructs. Sixteen 
hours post-transfection, cells were split 1:2 and cultured for 24 hours prior to fixation with PFA 
followed by propidium iodide staining. Cells were sorted by total DNA content and fluorescence 
to determine cell cycle distribution.  
  
  92 
 
 
 
Appendix E- Cdx2P-CreERT2 activity is restricted to the colon and distal ileum 
Mice carrying a floxed LacZ allele were treated with TAM to induce Cdx2P-CreERT2 expression. 
Staining for -galactosidase activity shows that Cre expression is restricted to the colon, cecum, 
and distal ileum. (Image courtesy of Ying Feng) 
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